WO2012158515A1 - Process for the preparation of protease inhibitors - Google Patents

Process for the preparation of protease inhibitors Download PDF

Info

Publication number
WO2012158515A1
WO2012158515A1 PCT/US2012/037515 US2012037515W WO2012158515A1 WO 2012158515 A1 WO2012158515 A1 WO 2012158515A1 US 2012037515 W US2012037515 W US 2012037515W WO 2012158515 A1 WO2012158515 A1 WO 2012158515A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
ring
group
aliphatic
Prior art date
Application number
PCT/US2012/037515
Other languages
French (fr)
Inventor
Gerald J. Tanoury
Original Assignee
Vertex Phamaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Phamaceuticals Incorporated filed Critical Vertex Phamaceuticals Incorporated
Priority to CN201280034614.0A priority Critical patent/CN103748059A/en
Priority to EP12723028.2A priority patent/EP2707346A1/en
Publication of WO2012158515A1 publication Critical patent/WO2012158515A1/en
Priority to IL229427A priority patent/IL229427A0/en
Priority to HK14110522A priority patent/HK1197229A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Definitions

  • Thfe invention relates to processes and intermediates -for the preparation of protease inhibitors, i particular,, serine protease inhibitors.
  • HCV hepatitis C virus
  • Protease inhibitors and in particular serine protease inhibitors, are useful ' in the treatment of HCV infections, as disclosed in WO 02/18369, WO 02/18369 also discloses processes and intermediates; to the preparat on; of these compounds. These processes lead to raeemizatioii of certain steric carbon centers. See, e.g., pages 223-22, As -result,, a need remains for enanuose!ective processes for the preparation of these compounds.
  • the present invention is directed towards processes- and intermediates for the preparation of ' protease inhibitors, particularly serine protease inhibitors.
  • the invention provides processes and intermediates ' . for producing bicyelic deri atives of formula is or lb;
  • rin A is a eyeloatiphatic ring
  • ring B is a heterocycio-aliphatic ring containing an additional 0 to 2 hetero atoms, each independentl selected from O, N. and S, thai can be optional iy substituted with 1 to 4 groups, each independently selected from alkyf halo, aikox , aryl. and hydroxy!;
  • t is H or a protecting group
  • S3 ⁇ 4 is ⁇ ⁇ , a protecting group, or Ci.r>- aliphatic.
  • One aspect relates to a process for preparing enantioseleettveS compounds -of formula, la or lb over compounds of formul s lc - Ih;
  • n R ?3 ⁇ 4 is. a. protecting group, in the presence of a compound of formula 111;
  • R.$ and R, 3 ⁇ 4 are each independently a
  • P008J Another aspect is di a compound of formula 30:
  • xvhereur ? is defined above, and 7,2 is H or a protecting group
  • step a treating the 2-anion of step a with carbon dioxide to produce enantioseleciively a compound of fpmuvla la;
  • compounds of the ⁇ invention may be optionally substituted with one or more suhstiiuents, such as are illustrated general ly above, or as exemplified by particula classes, subclasses., and species of the inventi n.
  • pharmaceutical agent includes two or more pharmaceutical agents, and so forth.
  • the term ' com ound refers t the eonipoimdf s) that are defined b structural formulas- respectivel drawn herein.
  • the term “compound " ' can include a salt of the eompound(s).
  • aliphatic encompasses the terms alkyl, alkenyl, alkynyL an cyeloaiiphatic, each of which is optionally substituted as set ibrth. below.
  • an "alky! group refers to a saturated aliphatic hydrocarbon group containing 1 -8 (e.g., 1-6 o 1-4) carbon atoms.
  • An alkyi group ca be straight, cyclic, or branched.
  • Examples of alky ! groups include, but are not limited to. .methyl, ethyi, propyl, i.sopropyL butyl, i so but l. ,yee-bnty], e/T-butyl «-pcntyl, tt-heptyl, or 2-ethylhexyi..
  • An alkyi group can be substituted (he., optionally substituted) with one or more substitiients selected from the group which consists of halt), cyeloaiiphatic (e.g., eyeloalky! or eyc!oaikenyl).
  • beteraeycloaliphatie e.g., heterocyc!oalkyi or heterocyclpal.ke.nyl
  • aryl heterDar l e.g., aikoxy, aroyh heteroaroyi
  • acyl e.g,, (aiiphahe ⁇ earbouyl, (cycloaliphaiic)carbonyL or (heteroeyc!oa!iphatj ⁇ carhonyl
  • nitro, cyano, amido e.g., (cycioalky!alkyi)carboByiarnirto, aryleatbonylamino, aratkyfearbonylauhno, (heterocydoalky car onylamino,
  • heterocyc!oalkylarninoearbony arylaminocarhonyl or heteroaiylammoGarbcmyl amino (e.g., aiiphati amino, cycloaiiphaticammo, or heterocycloaliphaticammo).
  • sulfotayl e.g.., aliphatic- SO2-
  • su!fmyl sirliarryl sulfexy urea, thiourea, suiianioyL sitltkniide, 0x0 ⁇ , earhoxy, carbamoyl, cye!oahphaticoxy.
  • heterocyeloah iharleoxy ar loxy.
  • substituted alkyls include earboxyalkyl (such as HQOC-alkyi, alkoxycarbonylalkyL and alkylearbonyloxyalkyl), eyanoalkyt, hydroxyaiky alkoxyalkyi acylalkyi, araikyl, (alkoxyaryl)aikyl, (su!i1 ⁇ 2 i rai o)atk i (such as ⁇ aik i-SOi-atnino ⁇ aikyl) ? aniinoaikyi, amidoalky I. (cycloalipiiaitcjalky!, and haioalkvi.
  • earboxyalkyl such as HQOC-alkyi, alkoxycarbonylalkyL and alkylearbonyloxyalkyl
  • eyanoalkyt hydroxyaiky alkoxyalkyi acylalkyi
  • araikyl such as alkoxyary
  • an "alkenyi” group refers to an aliphatic carbon grou (hat. contains 2-8 (e.g., 2-6. or 2-4 ⁇ carbon atoms and at least one double bond- Like an aikyi group, an alkenyi group can be straight or branched. Examples of an afken.yi group include, but are not l mited, to. allyl, isoprenyl 2-butonyl, and 2 iexenyl.
  • An alkenyi group can be- optionally substituted with one or more subslituenrs such as halo, cyctoaliphatle (e.g., eycloalkyl or cyc-loalkenyl) . , heterocycloaliphatic (e,g,, teterocycroaik l or
  • heteroeycloalkenyl aryl, heteroaryL alkoxy, aroyk hcteroaroyL acyl (e.g.,
  • heteroarylcarbonylaiTiino hete.roaralkylcarbonyiavnino a!kyianunocarbonyl.
  • heteroarylammocarbonyl amino (e.g., aliphatieamino, eycloaiiphatieamino,
  • heterocycioaliphaticamino . or aliphaiicsulfon la.mirio
  • sulfonyl e.g., alkyl-S(3 ⁇ 4-,
  • substituted alkenyls include eyaaoalkenyl,
  • an "aikynyP group refers to an aliphatic carbon group that contains 2-8 (e»g token 2-6 or 2-4] carbon atoms nd has at least one triple bond.
  • An ajkynyi group can be .straight or branched.
  • an alkyn l group examples include, but are not limited to, pro ajrgyl and butyriyi.
  • An alkynyl group can be optionally substituted with one or more substituents such- as aroyl, heteroaroyl, a ' lk xy, c eloalkvioxy ? heterocycloalky!oiiy, ary-bxy-, heteroaryloxy, aralkyiox , nit.ro, carboxy, eyano.
  • sulfanyl ⁇ e.g., aiiphaticsulfanyl or cycloahphaticsiuifenyl
  • sulfmyl e.g., aliphatiesulfmylor cyeloaiiphaiicsulfmyl
  • sulfonyl e. aUphatic-SCV,- afjphaiicamjno-SO?-, or cycloaSipliatic- $ ( 3 ⁇ 4- ⁇ , amido (e.g,, aminocarbonyl, . alkyiaiiiinocarbonyL a!kylearbonyiamino,
  • heteroaralkylearbonylamino heteroarylcarbonyl mino or heteroarylaminoearbonyl
  • urea f thiourea suliamoyL sul&mide
  • aikoxycarhonyi alkylcarbonyloxy
  • cyclojaBphatic heieroeydoaiiphatie
  • -ary-L heteroaryl acyi (e.g., eydoaiiphatic)earbonyl or
  • carbony 1 amino; ' when used al ne or m connection with another group, refer to an amido group such as - ( X )-C(() ⁇ - or ⁇ C(0) ⁇ N(R x h, when used terminally, and they refer to an amide group such as -G(0 - (R; )- or -N(R x ⁇ -C 0 ⁇ - when used internally, wherein R x and R Y are . defined below.
  • amido groups include aiky!atnido ⁇ such as alk lcarbonyl amino or alkyiaminocarbonyl), (heterocyeloaliphaticjamido,
  • amino refers to -NR:" , wherein each ot R ' and is independently selected .from hydrogen, aliphatic, eyclo aliphatic,
  • arylcarboTvyk (aral iphatic)carbonyl, (beieroeycloaliphai ic ⁇ ca.rbony] ,
  • (heteroara!ipha.tic)carbonyl each of which, being defined herein and is. optionally substituted.
  • amin gr ups include alkyianiino, diai&yiamino, and aryiamino.
  • amino s not the terminal group ⁇ e,g., aikylearbcTfiyiam.m ⁇ ) f: it is represented by -NR A -.
  • R A has the same meaning as defined above.
  • an ry ⁇ y group used alone or as part of a larger moiety as in “aralfcyP, "araikoxy " , or ⁇ aryi xyalkyl” refers to monocyclic (e.g., phenyl):, bieyelie ⁇ e.g., IndenyL naphthalenyk teirahydronaphthyi, tetrahydroinden i), and tricyclic (e.g., finorenyl tetraliydro&norenyi or tetrahydroanthracenyl, anthracenyi) ring systems m which the monocyclic rin system is aromatic or at least one of the rings in a bicyclic or tricyclic ring system is aromatic.
  • the bicyclic and tricyclic groups include benzofused 2- to 3-membered carbocyclic rings.
  • a ben ofused group includes phenyl fused with two or mor Q-s carboeycHe moieties.
  • An aryi is optionally substituted with one or more substituents, such as aliphatic (e.g.. alkyl, alkenyl, or aikynyl), cycioaiiphatic, (eyeioaliphaticialipbaiic.. heierocyc!oaHphatie, (heteiOcycioaliphaticjaiiphatie, aryi heteroaryk aikoxy,
  • substituents such as aliphatic (e.g.. alkyl, alkenyl, or aikynyl), cycioaiiphatic, (eyeioaliphaticialipbaiic.. heierocyc!o
  • suHbnyi e.g.. aiiphaiie-SOj- or annno-SOs-i siilflnyl (eg.. aiiphatic ⁇ S( ⁇ )) ⁇ or cycloaliphatic-S(O)-
  • su!fanyt e.g., allphatic-S-k cyano, halo, hydroxy, mercapto,, sulfbxy, urea, thiourea, sulfamoyl.. snilarnide, .and carbamoyl
  • an aryi can. be unsubstituted..
  • Non-limiting examples of substituted ary!s include haloaryl (e.g., mono-, di- (such as /3 ⁇ 4/is!-dihaloa:ryl ⁇ , or (trihalo ⁇ aryi).
  • (carhQxy)aryl e.g., (a!koxycarbonyl ⁇ aryl,
  • an "araliphaUe” group such as “aralkyl” refers to an aliphatic group. (e.g., a M alkyl group) that is substituted with an ary! group. Aliphatic,. aikyL and aryl are defined herein. An example of araiiphatie such as an aralkyl group is benzyl.
  • a " 'aralkyT group refers to an alkyl group (e.g., a Cj.4 alkyl group) that is substituted, with an aryl group. Both alkyl and ary! have been ' defined above.
  • An example of an aralkyl group is benzyl.
  • An aralkyl is optionally substituted with one or more .subsiituents such as- .aliphatic (e.g., substituted or mrsubsiituted alk l.
  • alkcnyl, or alkyriyl including carboxya!ky!, hydroxyalkyl, or haloalkyl, such as tri ' flitoromethyl ⁇ , cye!oaliphatic (e.g., substituted or unsubsiituted eycloalkyl or eyeloaikeny!),
  • heteroarylcarbonyiamino, or heieroaralkylcarbpnylamino cyano. halo, hydroxy, acyi, mercapto, aikylsulfanyL suifoxy. urea, thiourea, suliamoy!, sulfkmide, ⁇ ,. and carbamo l
  • a "bicycHc ring system” includes S- to 12- (e.g.. 9, 10, or 1 1) membered structures that, form two rings, wherein the two rings have at least one atom in common (e.g., 2 -atoms in common).
  • Sieve lie ring systems include bieyeloa!iphatics (e.g., hicycloa!kyl or bicycioa! keny l ⁇ , bicycloheieroaliphaties, bieyelie ary is, and bie ehc heteroaryls.
  • a " cycloaliphauc” .group encompasses a “cyctoslkyl” group and a “cyctoalkenyl " group, each of which being optionally substituted as set forth below, [00025]
  • a ⁇ eycloalkyl” group refers to a saturated carboeyclic motto- or bieyclic (fused or bridged) ring of 3-1:0 (e.g., 5-10) carbon atoms.
  • eycloalkyl group examples include eyelopropyl, cyclobutyk cyc!openty!., eyciohexyl, eyeloheptyk adamantyk norboniy cubyl, oeta.hydro-indenyl, decahydro-naphthvi bicyefoj3.2.1 ]ociyl,
  • a "cyeloa!kenyP group refers to a non -aroma tic earboeyclic ring: of 3-10 (e.g., 4.-8) -carbon atoms having one or more double bonds.
  • cycloalkenyl groups include eyelopentenyl, 1.4- cyc!ohexa-di-enyf, eyclohep enyl. eyclooctenyl, hexahydro-indenyL oetalxydro-naphthyk eyelohexenyi eyelopentenyl, bicyclo 2.2.2 ⁇ octenyl, and bieyclo 3 «3.1 jnonenyl,
  • a eycloalkyl or cycloalkenyi group can be o tionally substituted with one -or more substituents such as aliphatic (e.g., aikyi, alkenyl, or lkynyl), eycloaiiphatie, (eycloaiiphatie) .aliphatic, heteiOcyeloaliphatie, (heterocycioa!
  • ac l e.g., (eyc!oaliphatic)carbonyl, (cycloaiipbatic) aiiphatic)oarboiiyi (aral iphati e)c arbonyi , eterocyc loal iphatic k arbony 1,
  • 'cyclic moiety includes cycloaiipbatic, heteroeycloalipha ic, aryi,. or heteroaryl, each of which has been defi ned previously,
  • heterocyeloalkyl group and a heteroeycloaikeny 1 group, each of which being optionally substituted as set forth: below,
  • a refers to a 3-3 G nrembered BT BO- or bky!k (fused or bridged.) (e.g., 5- to 1.0-membered mono- or bkycik) saturated ring structure, in which one or more of the ring atoms is: heteroatom (e.g., N, 0, S, or combinations thereof).
  • heteroatom e.g., N, 0, S, or combinations thereof.
  • heterocycloalkyl group include piperidyi, piperazyl.
  • a monocyclic heterocyeloaiky! group can- be fused with a phenyl moiety such as tetrahydroisoquinoiine.
  • heteroeycioalkenyf' group refers to a mono- or bkylic (e.g., 5- to 10- membered mono- or bk el ) non-aromatic ring structure having one or more double bonds, and wherein, one or more of the ring atoms is a heteroatom (e,g, 5 N, (), or S), Monocyclic and bicydobete oaliphaiics are numbered according to standard chemica! nomenclature. [00029] A eterocycl.oalk ! or heteroeyekaenseyl. group can. be optionally substituted with one or m re sabstituenis such as. aliphatic (e.g., alkyk alkenyl, or alkyiiyl),
  • eyeloalipkUic eyeloalipkUic. :(cycIoaliphaUc)aHphatie. heierocycloaiiphatic, (heterocycioalipl icjalipbatic, aryL heteroar l, a!koxy, (cycioalsphatic)osy, (beierocycloa]ipbatic)os.y, aryloxy,
  • a "heteroary group refers to a monocyclic, bicycl c. or tricyclic ring system ha ving 4 to 15 ring atoms, wherein: one or more of the ring atoms is a heteroatom (e.g., N, ().. S, or combinations thereof) and in which the monocyclic ring system is .aromatic or at least one of the rings in. the bicyclic or tricyclic ring systems is aromatic,
  • a heteroaryl group includes a benzol used ring system, having 2 to 3 rings.
  • a benzofused group includes benzo fused wi h one or two 4 to 8 merabered.
  • heteroeycloaiiphatic moieties e.g.. indolizy!, indolyl LsoindoiyL 3H-indoIyl, indoiinyl.
  • heteroaryl are azetidinyl. pyridyl, 1 H-indazolyl, furyl pyrroiyi, thienyl, ihiazoiyi, oxazolyt imidazo!yl, tetrazolyi, benzofuryl, isoquinoiinyb benzthiazoiyl, xantheue, thioxanthene.
  • monocyclic heteroaryls include .fur l, thiophenyl, 2,11- pyrroiyi, pyrroiyi, oxasiolyl. thazolyi, imidazoiyi, pyrazolyi isoxazolyl, isothiazolyl, 1 ,3,4- thiadiazo!yi, 2H ⁇ pyranyl, 4-B-pranyl, pyridyl, pyridazyl. pyrimidyL pyrazoiyl, pyrazyl, and 1.3,.5-triazyl. Monocyclic heteroaryls are .
  • bicyclie heteroaryls include tadelizyl, mdoiy isoindolyi, 3ii ⁇ md lyL mdolkyk benzcsfi i:u : r l beozo /j thiopheayl ⁇ qumofinyl, isoquinoiinyl, indoiizyk isomdelvl, indo!yi, ben3 ⁇ 4ojd]i3 ⁇ 4ryL bexo[/?]thiophenyk indazolyl, benzb dazyk benzthiaaaiyh purinyk 4H-quinol.feyl J quinolyl, isoquinolyk einnolyk phtbalazyk qivhwq!yl, qu oxalyi, 1.8-naphtbyridyk and pieridvl.
  • Bicyclie heteroaryls include tadelizyl, mdoiy iso
  • a beteroarv I Is optionally substituted with one or more substituents such as aliphatic (e.g., alky I, alkenyl or a!kynyl), cyeloaliphatk, icycioaliphatic)aIipb.atie T beterocycloaiipbatic, (heterocycloaUphatie ⁇ aHphatic. aryk heteroaryl alkoxy,
  • substituents such as aliphatic (e.g., alky I, alkenyl or a!kynyl), cyeloaliphatk, icycioaliphatic)aIipb.atie T beterocycloaiipbatic, (heterocycloaUphatie ⁇ aHphatic. aryk heteroaryl alkoxy,
  • heteroaryl can be unsubstituted.
  • Non-limiting examples of substi toted heteroaryk include (halo)heieroaryi (e.g., mono- and di-(halo)heteroaryt), (carboKy)hcieroary! (e.g., (alkoxycarbonyi)hcieroary!), eyanoheteroaryi, mimo ' heteroaiyl. (e.g.. ((alkyisuli3 ⁇ 4iwI ⁇ amin:o)beteroaryl
  • heteroaralkyr group refers to an alkyl group (e.g., a CM alky] .group), that is substituted with, a ..he ternary! group. Both "alkyl " and 3 ⁇ 4 3 ⁇ 4eteroaryP have been defined above.
  • a heteroaralkyl is optionally substituted with one or more substituenis, such as .alkyl (including carboxyaikyh hydroxyalkyi and hatoalkyl such as triiluoromethvl).
  • an 4i aey! ' grou refers to a forniyi grou or R A -C(Q (such as alkyl-C(O . K also referred to as * 'alkylcarbonyr>- wherein. R: and alkyl have been defined previously. Acetyl and pivaloyl are examples of acyl groups.
  • an "aroyP or 'lieteroaro ⁇ refers to an ary kC(O)- o a heteroaryl-C(O)-, The aryl and heteroaryl portion of the aroyl or heteroaroyl axe opiionaily substituted, as previously defined..
  • an ''alkox ' group refers to an alkyl-O- group, wherein, alkyl has bee defined previ usly,
  • a "carbamoyl '5 grou refers to a group having the structure -O-
  • carboxy ⁇ group refers to -CQOH, -COOR , -OC(C) ⁇ B, or -
  • haloalinhatie group refers to an aliphatic group substituted with 1 -3 halogens.
  • haloaikyl includes the gr u ⁇ C . 3 ⁇ 4 ,
  • a "mercapto" group refers to -Sl i .
  • a "suiter' gr up refers to -S(3 ⁇ 4H or -S(3 ⁇ 4R X when used terminally and ⁇ S ; ( ⁇ 3 ⁇ 4- when used internally.
  • a "sulikmi-de-' group refers to the structure ⁇ NR A ⁇ S(0)2- N V Z when used terminally and - X -$
  • a "sulfonamide” group refers to the structure -Si O ⁇ 2-NR A K' or -NR x -S(0) 2 ⁇ R when used terminally and -SiO 2- R x - or -NR X -S(C))r when used
  • a ' ⁇ ulfanyp group refers to -S-R x when used terminally and - S- when used internally, ⁇ wherein R A has been defined above.
  • sulfanyl include al ' ipiiatie-S-, cycfoaliphatic-S-, and aryl-S-, or the like.
  • a suifinyl grou refers to -S(0) ⁇ R A when used terminally and - S(0)- when used internally, wherein R x has heen defined above.
  • Exeniple of sulfmyl groups include aliphatic-SCO)-, aryi-S(O -, (cyeloaliphalic(aliphatic) ⁇ -S(OK cycloalky 1- :S(Q)-, heteroeycioaliphaiie-SiC))--. and heteroaryi-S(0) ⁇ , or the like.
  • a "sulfony ⁇ group refers to ⁇ S(Q ⁇ 2-R ' when used terminall and - S(0) - when used internally, wherein R A has been deilned above.
  • Exemplary sulfonyl groups include aliphatic-SCO ⁇ ;-, aryl-S( ⁇ 3 ⁇ 4r f - ⁇ eycloaiiphatie(aliphatic):) ⁇ S O3 ⁇ 4-, eyeloaliphatie- (0)2-, heteroeycloal.ipba ie-S(0)r. heterpai l-S(03 ⁇ 4>- f and
  • a "sulf xy "5 group refers to -Q-SO-R or ⁇ SO-0 ⁇ R X when used terminally and -O-S(O)- or -S ' (0 ⁇ -0- when used internally, wherein R: x has been defined above.
  • halogen or "h l ' " group refers to fluorine, chlorine, bromine, or iodine:.
  • an "afkoxyalkyf * group refers to an alkyl group such m. alkyl-O- alkyk wherein alkyl has been defined above.
  • a "carbonyr * group refer to -C(0 ⁇ -.
  • an 3 ⁇ 4 ⁇ ! ⁇ group refers to; :::: 0.
  • aminoalkyl refers to the structure ⁇ R x 2 -alk k
  • a "eyanoalkyl group refers to the structure ⁇ NC)-alkyl-.
  • are grou refers to the structure -N X -C()-MR3 ⁇ 4 and a "thiourea " group refers t the structure -NR X - €S ⁇ NR3 ⁇ 4 Z when used terminall and -KR S - CO-NR ' ⁇ or -NR X -CS-MR Y - when used internally, wherein R x , R Y , and R z have been defined above.
  • an "amid no" grou refers to the structure -C ::: fHR x )N ⁇ R x R ).
  • the term "vicinal” refers to the placement of substituents on a grou : that includes two or more carbon atoms, where n, the substituents are attached to adjacent carbon atoms.
  • geroinaP * refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to the same carbon atom
  • terminal and 'Internally refer t the location of a group within a substitueni.
  • a group is terminal when the group is present at the end of the substitueni and not further bonded to the rest of the chemical structure.
  • Caybox.yalk.yL i.e.. R x O(0)C ⁇ al.kyl is an example of a earboxy group used terminally,
  • a group is internal when it is not terminal Alkylcarboxy (e.g., a!kyl-C(O)-C)- or alkyl-O-C(O)-) and aikyiearboxyary!
  • cyclic group includes mono-, hi-, and tri-cyciic ring systems, such as cycloaliphaiic. heteroeyeloaHphatic, aryl. and. heteroaryl. each of which has been defined: above.
  • a "bridged hieyclie ring system” ' refers to a bicyclie
  • bridged bicyclie ring systems include, but. re not limited to, adamantanyL norbornanyl, bicyclo 3.2.1 fociyi bicycla[ .2 : ;2 ⁇ dctyl- bicyclo[3.3.1 jnonyl btcyeIo 3,2.3]nonyL 2 >xabieycio 2.2.2 ' joctyL l-azabieyc!o[2.2.2JoctyK 3- azabkycjop.2:J]oetyl, and 2,6-dioxa-iriCyclo[3,3.1.O ⁇ jnonyi
  • a bridged bicyclie ring system can be optionally substituted with one or more substituent such as alkyl (including carboxyaikyL bydroxyalky!, and hal
  • heteroaralkyloxy aroyf heteroaroyl, nit.ro, earboxy, aikoxycarbonyl, alkylearbony!oxy, ammoearbonyl aikylcarbonylaraino, eycloaikylearboBylamino, (cyc
  • an "aliphatic chain" refers to branched or straight aliphatic group (e,g., alkyl groups, alkenyl. groups, or alkynyl groups).
  • A. straight aliphatic chain has the structure -( €3 ⁇ 4)*-, where v is 1 -6,
  • a branched aliphatic chain is : a straight aliphatic chain that is substituted with one or more aliphatic groups.
  • a branched aliphatic chain has the structure -(CMQ y-, where y is 1.-6 and Q is hydrogen or an aliphatic group; however, Q shali be an aliphatic group in at least one instance.
  • the term aliphatic chain includes alkyl chains, alkenyl chains, and alkynyl chains, where alkyl. alkenyl and alkynyl are defined above,
  • the phrase "optionally substituted” is used interchangeabl wit the phrase “substituted or unsubstituted.”
  • compounds of the in vention can optionally be substituted with one or more substituents; such as; are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • the variables 3 ⁇ 4, 3 ⁇ 4, ? . and .3 ⁇ 4., as well as other variables encompass specific groups, such as alkyl and ary!. Unless otherwise noted, each of the specific groups for the variables R 5 , .
  • 3 ⁇ 4, 3 ⁇ 4, and 3 ⁇ 4, : and other variables contained therein can he optionally substituted with one or more substituents described herein.
  • Each substituent of a specific group is further optionally substituted with. one- to three of halo, cyano, oxo, alkoxy. hydroxy, amino, nitro, aryl cye!oaliphatic, heierocyeloaliphatic, heieroaryl, haloalkyl. and alkyl.
  • an alkyl group can be substituted with aikylsulianyl, and the alkylsultany] can be optionally substituted with one to three of halo, cyano, oxo. alkoxy. hydroxy, amino, nit . ro, . aryLhaloalk-yi, and -alkyl.
  • (eycloaikyl)ca bonyiamino can be optionally substituted with one to three of halo, cyano, alkoxy. hydroxy, nitro, haloalkyl, and alkyl.
  • the tw alkxoy groups can form a ring together with the atorn(s) to which they are bound.
  • substituted/ refers to the replacement of hydrogen radicals in a gi en structure with the radical of a specified substituent.
  • substituents are described above in the definitions and below in the description of compounds and examples thereof Unless otherwise indicated, an optionally substituted group can have a substituent at each substifiuable position of the group, and when more than one position in any gi ven structure can. be substituted with more than one su ituent selected from a specified group, the subsiitueni can be either the same or different at every position.
  • a ring snbstiluent such as a heterocycloa!kyl
  • Combinations of subsiituenis envisioned by this invention are those combinations thai result in the formation- of stable o chemicall feasible compounds.
  • a stable compound or chemically feasible compound refers to compounds that are not substantially altered when subjected, to conditions to allow for their production, detection, and preterahly their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one .that is not substantiall altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week,
  • the phrase "preparing enaMi vSe!eeiive.iy' '> refers to asymmetric synthetic preparation of enantiomerica!ly-enriched compounds. This is further defined as the use of one or more techniques to prepare the desired compound in high enantiomeric excess (i.e., 60% or more).
  • the techniques encompassed may include the use o chirai starting materials (e.g., -chirai pool synthesis), the -use of.chiral auxiliaries and chirai catalysts, and the. application of asymmetric induction,
  • ⁇ enantiomeric excess' or ⁇ e.e,, ** refers to the optical purity of a compound.
  • encfa.'exo refers to the ratio of e3 ⁇ 4fo ⁇ iso.mers to exo-iso ers.
  • '"enantiomeric ratio is. the. ratio of the percentage of one enantiomer in a mixture to that of the other,
  • a "protecting group” is defined as a group that is introduced into a molecule to modify a functional group present in a molecule to prevent It from reacting in a subsequent chemical reaction and thus obtain chemoseleciivity. it is removed from the molecule at a later step, in the synthesis.
  • a carbobenzyloxy (Cbz) group can. replace the hydrogen on a amine to prevent it front reactin with an eieetrophile, then the. Cbz group can: be removed by hydrolysis in a later step.
  • Acid and amine protecting groups as used herein are: known: in the art (see, e.g., T.W. Greene & P.G.M Wutz, - 'Protective Groups in Organic Synthesis.” .3** Edition, John Wiley & Sons, inc. (1999)),
  • suitable protecting groups for acids include ttn- butoxy, benzyloxy, all ioxy, and inethoxyrnethoxy.
  • Suitable protecting groups for amines include 9-fi.tioreny.lmeth l carbamate, /er/ x «yf carbamate,, benzyl carbamate, irifiaoroaeeianiide, and p-teluenesuifonarnide; 007 ]
  • a "effective amount ' ' is defined a the amount required to. confer a tberapeiitic effect: on the treated patient and is typically determined based on age, surface area, weight and condition of the patient.
  • Body surface area may be approximatel determined from height and weight of the patient. See, e.g.. Scientific ' Tables, eigy
  • patient refers to a mammal, including a human.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diasiereomeric, and geometric (or conformational)) tottns of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (Ej conformational isomers.. Therefore, single isomeric (e.g., enantiomeric, diasiereomeric, and geometric (or conformational)) tottns of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (Ej conformational isomers.. Therefore, single isomeric (e.g., enantiomeric, diasiereomeric, and geometric (or conformational)) tottns of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond is
  • structures depicted herein are also meant to include compounds thai differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the. replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 'C- or 14 C-enriehed carbon are within the scope of this invention.
  • Such compounds are useful, for example * as analytical tools or probes in biological assays,
  • E ' DC is l H3 ⁇ hmethyiaminopropyl ⁇ 3-ethylearbodiimlde.
  • HBf is 1 -hydroxybenzotriaEole
  • Cbsf is beuzyloxyearbonyi is DCM
  • dichloromethane is dichloromethane
  • Boc "' is k?ri"-butoxycarhonyl
  • Hi N stands for proton nuclear magnetic resonance
  • TLC * stands for thin layer chromatography
  • the invention provides processes and. intermediates for producing bicyclic derivatives of formula la or lb:
  • ring A is a C 3 . 12 cycfoal phatie ring;
  • ring B is a G . s ?. beteroeycioaHphatic ring containing an additional 0 to 2 heiero atoms , each independently selected from O, M, d that can be optionally substituted with 1 to 4 groups, each independentl selected from alkyl, halo, alkoxy, aryL and hydroxy!;
  • Ri is H or a protecting group:
  • R? is H or C ⁇ - ⁇ 2 aliphatic
  • ring A is a C3-6 cycloaliplmtic ring.
  • ring A is eycIopfopyL
  • ring A is -dimeth leyclopropyL
  • ring B is aryL
  • ring B is phenyl. 100 901 More : particularly, ring B is:
  • .ring B is a S-raembered: heterocyclic ring.
  • nne B nne B
  • ring B is substituted with a aryi ring optionally substituted with I to 4 groups, each independently selected .firom lkyl, halo, alkoxy, and hydroxy L
  • j is H.
  • 5 is a protecting group.
  • R 2 is ii.
  • .3 ⁇ 4 is methyl ethyl, ff-propy!, im- ISO- b tyl, -w-peuty or i.w-penty;L
  • R 2 is fto-butyl
  • R 2 is /ert- uiyl. 1000104]
  • 3 ⁇ 4 is a c eloabphatic ring.
  • Another aspect relates to a process for preparing enaniioselectlvely compounds of formula. la or lb over com ounds of formi as ⁇ lb:
  • R ;!l is proteciing group, und of formula III:
  • R; and R4 are each independently a protecting group, C .n aliphatic, or a cyclic group selected from the group consisting of cyeloallphatic, hetcrocveioaiiphatie. aryh and heteroaryi
  • R is is i r/ ⁇ butyl carbamate (Boc .
  • the step of carboxyiating a . compound of formula II is in the presence of a compound of .formula Ilia:
  • the step of carboxyiating a compound of formula 0 is in the presence of a compound of .fo
  • the step of carboxyiating a compound of formula I ! is in the presence of a compound of formula. Hid;
  • 3 ⁇ 4 is C n aliphatic
  • 13 ⁇ 4 is C . unbranched aSkyl.
  • l t is CM branched alky!
  • is Cw branched a!kyL substituted with a cyclic group.
  • R 4 ls C M branched alkyl, substituted with a phenyl group.
  • iii s a cyclic group.
  • !3 ⁇ 4 is a bkyclie group.
  • the arboxylaiion step comprises treating compound of formula Ha or Ob with carbon dioxide and a lithi um base in the presence of an aproite solvent.
  • the aprotic solvent is selected from the group consisting of toluene, ethyl aeetate ? benzene, and methyl te'i-butyl ether (MTBE).
  • the aprotic solvent is MTBE.
  • the lithium base is .3 ⁇ 43 ⁇ 4' >iityl lithium.
  • the process of the present invention gives rise to a mixture of products including H a (exo% 1-3 (ex& 1-2: (endo), and 14 (emfo),
  • the combined . " weight percent in a mixture comprising eonvpotmds of formula la and .(the e:3 ⁇ 4:o-isomers) and compounds of ormula Ic and le (the endo4somtti) : is 100 weight percent, [000126] In one embodiment, the ratio of the eombined weight pereent of ia and id (exo- isomers): to: thai of le and le ( do-iso ets) is at least 60 to 40.
  • the ex&fendo ratio is at least 80 to 20.
  • the exafemh ratio is at least 90 to 10.
  • the exol ' endo ratio is at least 95 to 5.
  • the process further comprises the. step of removing a portion o the compounds of formula Ic and/or le f om Che produet mixture.
  • the compounds .of formula le and/or k are removed by crystallizing the compound of formula la or lb.
  • the compounds of formula Le and/or le are removed by recrysiailrang the -compound of formula ia or lb.
  • the ratio of the weight percent of la to Id is at leas 60 to 40. $00135] More particularly, the ratio of the weight percent of la to Id is at least 80 to 20, [0001 M] More particularly, the ratio of the weight percent o la to Id is at least 90 to 10, [000137) More particularly, the ratio of the weight percent of la to Id is at . least 95 to 5.. 000138] More particularly, he ratio of the weight percent of la to Id is at least 99 to 1 f 000139] More particularly, the ratio of the weight percent of la. to Id is at least 99.6 to 0,4. 1000140] More particularly 1, the ratio of the weight percent of la to id is at least 1 0 to 0, [000141 ] Another aspect is d a compound of formula 1 :
  • step a treating the 2-anion of step a with carbon dioxide to produce
  • the compound. of formula II ⁇ is a compound of formula Ola. ⁇ 43)
  • the com ound of formula HI is a compound of forraula Illb. ⁇ O0144
  • the compound of formula 26 is the compound of formula 26-a:
  • Another ispeci relates to a: compound of formula la-4 made by the processes
  • the compound of formula 10 is a compound of i rmul I0-a f wherein ⁇ s H f and 3 ⁇ 4is /erz-hutyl.
  • Another aspect relates to a compound of formula 10-b made y the processes disclosed herein:
  • the compound of formula 10 is a compound of formula 10-b, wherein Z? is H, and >is im-butYl. 000155] Another aspect relates to a compound of formula 10-d made by the processes
  • the invention provides: a process and intermediates for preparing a compound of formula. la as outlined in Scheme i, wherein Rj, R3 ⁇ 4 Ri, R4, and rin A are previously defined.
  • Carboxylation of the compound of formula Ilk is : achieved by first forming a 2- anion of ibrmula Ha in the presence of a compound of formula IIL
  • a compound of formula IIL For formation of similar anions, see, ,g Berry Daniel. J. Pippel, et, al, J. Org: O em., 199 , 63. 2; Donald J. Gallagher et at, J. Org. ahem., 1995, 60(22), 7092-7093: Shawn T. Kerrick. et al, ⁇ l Am. Chem, Sac. 199-1 , ⁇ 3.(25), 9708-9710; Donald .1. Gallagher et al., J Org. Chem.
  • the 2-anion of formula Ha (not. shown in Scheme 1 ⁇ is prepared by treatment of compound of formula. I la with a strong lithium base (e.g., ,vec-butyiliihiura or isopmpylliihium in a. suitable aprotic solvent (e.g., MTBE, diethyletlier, or toluene) in the presence of a compound of formula III.
  • a strong lithium base e.g., ,vec-butyiliihiura or isopmpylliihium in a. suitable aprotic solvent (e.g., MTBE, diethyletlier, or toluene) in the presence of a compound of formula III.
  • An optically acti ve compound of formul HI can induce enantioselective earboxylation to give a product having an enantiomeric excess (e.e.) of from abo t 10% t about 95% (see, e.g.. Beak c d., J. Org. Chem., 1 95, 60. 8148-S154 .
  • a compound of ibrmula Ila can be treated with carbon dioxide to give a mixture of exo ndo compounds, wherein the ex.o enda ratio is 60 to 40, 80 to 20, 90 to 1 (L 95 to 5, or greater than 98 to 2.
  • Scheme H I depicts the reaction of a compound of form ula -26- with a compound of formula la to form a compound of fo-rmuia ' 28, wherein R? is defined ' above.
  • eoinpoun.ds of formula 28 are intermediates in the synthesis of protease inhibitors according to Scheme IV .
  • Removing the protecting group Z in the tripeptide. of formula 30 provides a tree amino- tripeptide of formula 31.
  • Reaction of the aniino-tripeptide of formula 31 with the pyra ine- ' 2- carbosyHc acid of formula. 32 in the presence f a coupling reagent yields the amide- tripeptide ester of formula 33.
  • Hydrolysis of the ester of the amide- iri peptide ester of formula 33 provides the amido-tripeptkie acid of formula 34.
  • Reacting the amido-tripeptide acid of formula 34 with the amino-hydroxy amide of formula 18 to the presence of a coupling reagent gives the hydroxy-peptide of formula 35.
  • oxi dation of the hydroxy grou of the compound of formula 35 pro vides the compound of formula 4.
  • the process of Scheme HI can be scaled for large-scale production, e.g. in a manufacturing plant.
  • Large scale production can. for example, be sealed to greater than .1000 kilos.
  • aqueous NaHSCX (twice, 145 mL each) and water (1.45 mL). It was then concentrated to 300 mL unde vacuum. MTBE (300 mL) was added, a d the mixture was concentrated to reduce the water concentration to less tha 550 ppm. The concentrate was diluted with -MTBE (400 mL) to provide a solution of the title compound in MTBE.
  • the organic phase was heated to about 35 °C, diluted with DMF (300 mL), and concentrated at reduced pressure to the po nt at which distillation slowed significantly, leaving about 500 mL of concentrate.
  • the concentrate was iransfcrred without rinsing to a 1 L Schot batik.
  • the concentrate, a clear colorless solution weighed 1 1.6 g, Eksed on solution, assay analysis and the solution weight, the solution contained 187,2 g (0.706 ' mol) of
  • thermocouple, addition funnel and nitrogen inlet were charged H0BT « i3 ⁇ 4( (103.73 g. 0.678 mol 1 .20 molar eq.), EDC'HCI (129.48 g, 0.675 mol, 1 .20 molar eq.% and DMF (480 mL).
  • the slurry was cooled to 0 to 5 °C.
  • a 36.6 weight percent solution of the acid of Cbz-L-fer/- Leueine in DMF (4 1.3 , 0.745 mol., 1.32 molar eq.) was added over 47 minutes to the reaction mixture, while keeping the temperature at 0 to 5 °C.
  • the reaction mixture was stirred for 1 hour and .27 minutes.
  • the aqueous phase was; extracted with isopropyi acetate (716 m.L), and the organic phases were combined, 1 aqueous hydrochloric acid was prepared by adding 37 weight percent hydroehlorie acid ; C123 ⁇ 4.3 ml) to water ( 1435 mi). The organic phase was washed for about 20 minifies with the 1 N hydrochloric acid.
  • a 10 weight percent aqueous potassium, carbonate solution- was prepared by dissolvin potassium: carbonate (171 g, 1 .23 rool, 2.1 molar eq.) in water ( 154D nil,). The organic phase was washed with, the 10 weight percent aqueous-potassium carbonate solution for about 20 minutes.
  • the .final clear, pale yellow organic solution (1862.1 gL was sampled and submitted for solution assay. Based on. the solution, assay and the weight of the solution, the solution, contained 2.38.3 g (0.520 tnoi) of product of the title compound,
  • earboxyJate (as prepared by the method of Example 6, Method, t) in isopropy! acetate (3.9.39 g, 0.086 mol) was charged to the reactor, Isopropy! acetate (100 mL) was added to the reactor, A slurry of 50% water and wet 20% Pd( 013 ⁇ 4/earbon (3.97 g) in isopropyl acetate (168 m.L) was prepared and charged to the reactor, and agitation was started. ' The reactor was pressurized to 30 psig with nitrogen gas and vented, down to atmospheric pressure. This was repeated twice. ' Then, the reactor was pressurized to 30 psi with hydrogen and vented down to atmospheric pressure. This, was repeated twice.
  • the reactor was pressurized to 30 psig with hydrogen and stirred, at mbient temperature for 1 hour.
  • the mixture was filtered using a Buehner funnel with a Whatman #! filter paper to remove the catalyst.
  • the filter cake was. washed with isopropyi acetate (SO mL),
  • the ocedur was repeated twic more using 617 g and 290.6 g of the 12.8 weight percent solution of the starting compound.
  • the material from the thre hydrogenations were combined and distiiied at reduced pressure (28 torr).
  • the resultant solution (468.68 g) was assayed for the titl compound,

Abstract

A process for preparing enantioselectively a compound of formula (la) or (Ib) over a compound of formulas I-2—1h.

Description

PROCESS FOR THE PREPARATION OF PROTEASE INHIBITORS
Cross-Kefereiice to Related Applications
[0Θ81| This application claims the: benefit of priority of U.S. Provisional Application Ho. 61 /4864.50, filed: May 13, 201 1 , which is incorporated heroin as reference.
Field of the ItiveBiio-tt
002j Thfe invention relates to processes and intermediates -for the preparation of protease inhibitors, i particular,, serine protease inhibitors.
Background of th Invention
JO0O3) Infection by hepatitis C virus ("HCV") is a compelling human medical problem. HCV is recognized as the causative agent for most cases ofnon-A. and non-B hepaii is with a estimated human sero-prevaience of 3% globally (A, Albert! et ai,, "Natural History of Hepatitis C,'V, Hepato g y 31 (Suppi IX pp. 1 7-24 (1999)}, Nearly four million individuals may be infected in the United States alone. (M,J, Alter et ah, "The Epidemiology of Viral Hepatitis in the United States." Gastroenterol Clin, tforfk Am... 23, pp. 437-455 (1994); M. i Alter "Hepatitis C Virus infection in the United States," J Hep toiogy, 3 l (Suppi. pp. 88-91 ( 1999)).
| ί>04] Upon first exposure to HCV, only about 20% of infected individuals develop acute cluneal hepatitis, while others appear to resolve the infection spontaneously. In. almost 70% of instances, however, the virus establishes a chronic infection that may persist for decades. (S. iwarsop, 'The Natural Course of Chronic Hepatitis," F MS Microbiology Reviews, 14, pp. 201 -204 (1994); P. Lavanehy. "Global Surveillance and Control of Hepatitis C3' J Vital Hepmitis* 6. pp. 35-47 (1 99)}, Prolonged chronic infection can result i recurrent and progressively worsening liver inflammation, which Often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma. (MC. Kew» "Hepatitis C and Hepatocellular Carcinoma " FEMS Microbiology R views, 14, pp. 21 1-220. (1 94); i . Saito et. al., "Hepatitis C Virus Infection is Associated with the Development of Hepatocellular Carciliop a " Froc. Nail Ae d Set USA, 87, pp. 6547-6549 (1990)), Unfortunately, there are no broadly effective treatments for the debilitating, progression of chronic HCV,
(01)115} Protease inhibitors, and in particular serine protease inhibitors, are useful' in the treatment of HCV infections, as disclosed in WO 02/18369, WO 02/18369 also discloses processes and intermediates; to the preparat on; of these compounds. These processes lead to raeemizatioii of certain steric carbon centers. See, e.g., pages 223-22, As -result,, a need remains for enanuose!ective processes for the preparation of these compounds.
Sunisnasy of the Inventkm
[00061 'This and other needs are met by the present invention, which is directed towards processes- and intermediates for the preparation of 'protease inhibitors, particularly serine protease inhibitors. In. one aspect, the invention provides processes and intermediates'. for producing bicyelic deri atives of formula is or lb;
Figure imgf000004_0001
wherein:
rin A is a eyeloatiphatic ring;
ring B is a heterocycio-aliphatic ring containing an additional 0 to 2 hetero atoms, each independentl selected from O, N. and S, thai can be optional iy substituted with 1 to 4 groups, each independently selected from alkyf halo, aikox , aryl. and hydroxy!;
t is H or a protecting group: and
S¾ is ί ϊ, a protecting group, or Ci.r>- aliphatic.
O07j One aspect relates to a process for preparing enantioseleettveS compounds -of formula, la or lb over compounds of formul s lc - Ih;
Figure imgf000005_0001
fla li
where n R is. a. protecting group, in the presence of a compound of formula 111;
Figure imgf000005_0002
wherein R.$ and R,¾ are each independently a
Figure imgf000006_0001
group selected from the group consisting of eyeioaliphatie, heteroeycloalipliatic. atyi and heteroaryl.
P008J Another aspect is di a compound of formula 30:
Figure imgf000006_0002
10
xvhereur ? is defined above, and 7,2 is H or a protecting group;
comprising the steps of:
a. fomiing. a 2 -anion of a. c mpo nd of formula Ha:
Figure imgf000006_0003
ila
wherein Ri* and ring A are defined above, in the presence of a compound of formula ΙΠ:
Figure imgf000006_0004
wherein lis and ftj are defined above;
treating the 2-anion of step a with carbon dioxide to produce enantioseleciively a compound of fpmuvla la; and
reacting the compound of fbrmuk la witli a compound of formula
Figure imgf000007_0001
26
wherein Z<) is a protecting group,
Detailed Beseriptioa of the ¼vej¾f ίάη
Defmiiio
10009} For the purposes of this invention, the chemical elements are identi fied in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics,
15 t Ed< Additionally, genera! principles of organic chemistry are described by Thoma
SorreSi in Organic Chemistry, University Science Books, Sansalito ( 1999% and by M.B.
Smith and J. March in Advanced Organic Chemistry, 5lh Ed., John Wiley & Sons, Mew York
(2001), both of which are hereby incorporated by reference.
[000101 As described herein, compounds of the■■invention ma be optionally substituted with one or more suhstiiuents, such as are illustrated general ly above, or as exemplified by particula classes, subclasses., and species of the inventi n.
[00011]' It must be noted thai as used herein and in the claims, the singular forms "a, 11
"an " and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a binder" includes two -or more binders, and reference to "a
pharmaceutical agent" includes two or more pharmaceutical agents, and so forth.
[00012] As: used herein, the term '"com ound" refers t the eonipoimdf s) that are defined b structural formulas- respectivel drawn herein. Furthermore, unless otherwise stated, the term "compound"' can include a salt of the eompound(s).
[00013] As used herein, the term "aliphatic" encompasses the terms alkyl, alkenyl, alkynyL an cyeloaiiphatic, each of which is optionally substituted as set ibrth. below.
[00014] As used herein, an "alky!" group refers to a saturated aliphatic hydrocarbon group containing 1 -8 (e.g., 1-6 o 1-4) carbon atoms. An alkyi group ca be straight, cyclic, or branched. Examples of alky ! groups include, but are not limited to. .methyl, ethyi, propyl, i.sopropyL butyl, i so but l. ,yee-bnty], e/T-butyl «-pcntyl, tt-heptyl, or 2-ethylhexyi.. An alkyi group can be substituted (he., optionally substituted) with one or more substitiients selected from the group which consists of halt), cyeloaiiphatic (e.g., eyeloalky! or eyc!oaikenyl).
beteraeycloaliphatie (e.g., heterocyc!oalkyi or heterocyclpal.ke.nyl), aryl heterDar l, aikoxy, aroyh heteroaroyi, acyl (e.g,, (aiiphahe}earbouyl, (cycloaliphaiic)carbonyL or (heteroeyc!oa!iphatj^carhonyl), nitro, cyano, amido (e.g., (cycioalky!alkyi)carboByiarnirto, aryleatbonylamino, aratkyfearbonylauhno, (heterocydoalky car onylamino,,
(heierocycloalkykh.^
¾eter¾aralkylcarbonyiaramo alkylam ocarbonyh eyck>alkylarainocarbonyi.
heterocyc!oalkylarninoearbony arylaminocarhonyl or heteroaiylammoGarbcmyl), amino (e.g., aiiphati amino, cycloaiiphaticammo, or heterocycloaliphaticammo). sulfotayl (e.g.., aliphatic- SO2-), su!fmyl sirliarryl sulfexy, urea, thiourea, suiianioyL sitltkniide, 0x0·, earhoxy, carbamoyl, cye!oahphaticoxy. heterocyeloah iharleoxy, ar loxy. heteroaryloxy, aralkvloxv. heteroaiylalkoxy, alkoxycarbonyl, alkylcarbon.ylox.yv and hydroxy. Without limitation, some examples of substituted alkyls include earboxyalkyl (such as HQOC-alkyi, alkoxycarbonylalkyL and alkylearbonyloxyalkyl), eyanoalkyt, hydroxyaiky alkoxyalkyi acylalkyi, araikyl, (alkoxyaryl)aikyl, (su!i½ i rai o)atk i (such as {aik i-SOi-atnino}aikyl)? aniinoaikyi, amidoalky I. (cycloalipiiaitcjalky!, and haioalkvi.
fOi iSj A used herein, an "alkenyi" group refers to an aliphatic carbon grou (hat. contains 2-8 (e.g., 2-6. or 2-4} carbon atoms and at least one double bond- Like an aikyi group, an alkenyi group can be straight or branched. Examples of an afken.yi group include, but are not l mited, to. allyl, isoprenyl 2-butonyl, and 2 iexenyl. An alkenyi group: can be- optionally substituted with one or more subslituenrs such as halo, cyctoaliphatle (e.g., eycloalkyl or cyc-loalkenyl)., heterocycloaliphatic (e,g,, teterocycroaik l or
heteroeycloalkenyl), aryl, heteroaryL alkoxy, aroyk hcteroaroyL acyl (e.g.,
;(a.iiphaiie)earbon.yl, (eyc.ioalipl . ic)carbonyi, or (hetcrocyeloaltphatie)carbonylh nitro, cyano, amido (e.g., fcyeloaikyialkyjjearbonykmmo, ary!earbonyianimo, ara!kyicarbonylamino, (he erocycio.alkyl)c:arbonylaniino, (heteroeyel.oa.ikyialky!}carbo
heteroarylcarbonylaiTiino, hete.roaralkylcarbonyiavnino a!kyianunocarbonyl.
cycloalkylani-inocarbonyJ, heter cycioalkylami.noe.arbonyl. arylai«inoearb0nyl.¾ or
heteroarylammocarbonyl), amino (e.g., aliphatieamino, eycloaiiphatieamino,
heterocycioaliphaticamino,.or aliphaiicsulfon la.mirio), sulfonyl (e.g., alkyl-S(¾-,
cyeloaliphatie-SO?-, or.aryl~S0j-}> sulfinyi, sulfanyl. sulfbxy, urea, thiourea, sul-famoyl, sulfamide, oxo, earhoxy, carbamoyl, cycloaliphaheoxy, heteroeyeioaliphaticoxy, aryloxy, heteroaryloxVj aralkvloxv. heteroaraikoxy, alkoxycarbonyl, alkyicarbonyloxy, and hydroxy. Without limitation, some examples of substituted alkenyls include eyaaoalkenyl,
aJioxyalkenyi, acylalfcenyl, hydroxyalkenyl, aralkenyJ, (alkoxyaryl)alkeny i,
(suli nylanwno}alkenyl (such as (alkyI-SO- -ammo)alkenyl)- aminoalkenyl, amkioalkeny (c:yeloaiiphatie)aikenyls and haloaikenvL $00161 As used herein- an "aikynyP group refers to an aliphatic carbon group that contains 2-8 (e»g„ 2-6 or 2-4] carbon atoms nd has at least one triple bond. An ajkynyi group can be .straight or branched. .Examples of an alkyn l group include, but are not limited to, pro ajrgyl and butyriyi.: An alkynyl group, can be optionally substituted with one or more substituents such- as aroyl, heteroaroyl, a'lk xy, c eloalkvioxy? heterocycloalky!oiiy, ary-bxy-, heteroaryloxy, aralkyiox , nit.ro, carboxy, eyano. halo, hydroxy, sul:i¾ inercapto, sulfanyl {e.g., aiiphaticsulfanyl or cycloahphaticsiuifenyl), sulfmyl (e.g., aliphatiesulfmylor cyeloaiiphaiicsulfmyl),. sulfonyl (e. aUphatic-SCV,- afjphaiicamjno-SO?-, or cycloaSipliatic- $(¾-}, amido (e.g,, aminocarbonyl,.alkyiaiiiinocarbonyL a!kylearbonyiamino,
cycloaikylaniinoearhonyl, heterocycloalkylaminocaxbonyl, eyeloalkykarbonylamino, arylaminocarbonyf arylcarbonylamino, a alkylcarbonyiamino,
(heteroeyck'5alkyl}carbonylamtno:, (eycloalkyialkyljcarbonylammo,
heteroaralkylearbonylamino. heteroarylcarbonyl mino or heteroarylaminoearbonyl), ureaf thiourea, suliamoyL sul&mide, aikoxycarhonyi, alkylcarbonyloxy, cyclojaBphatic, heieroeydoaiiphatie, -ary-L heteroaryl, acyi (e.g., eydoaiiphatic)earbonyl or
(h.eterocyc{oaliphatie)carbonyl)> amino (e.g., aHphaticanii.no)- su!fox , oxo, carhoxy, carbamoyl, (eydoaliphatiejoxy, (heieroeycloa!ipha.tic:}oxy and (lieteroaryl)alkoxy,
{00017} As used herein, an "amido" encompasses both "ammocarbony and
"carbony 1 amino; ' These terms, when used al ne or m connection with another group, refer to an amido group such as - ( X)-C(()}- or ~C(0)~N(Rx h, when used terminally, and they refer to an amide group such as -G(0 - (R; )- or -N(Rx}-C 0}- when used internally, wherein Rx and RY are . defined below. Examples of amido groups include aiky!atnido {such as alk lcarbonyl amino or alkyiaminocarbonyl), (heterocyeloaliphaticjamido,
(heteroaralkyl)amido, (heteroaryl)amtdo, iheierocyeioaikyl)aIkyIamidp, arylarmdo, araikylamido, (cye|oaikyl)alky!amido. and eyc!oalkylamido,
[00018) As used herein, an "amino" group refers to -NR:" , wherein each ot R' and is independently selected .from hydrogen, aliphatic, eyclo aliphatic,
(cycloaliphatic)aliphatic, aryl, araliphatie, heteroeycloalipbatie,
(heterocycioa3iphatic)allphatic, heteroaryi, carboxy, sulfenyk sulfinyl, sulfonyl,
(aliphatic)earbonyl, (cyeloaliphatic)carbonyl f{cyeloatiphatic)aliphaiic)carbonyL
arylcarboTvyk (aral iphatic)carbonyl, (beieroeycloaliphai ic}ca.rbony] ,
{(heterocyc!oaliphatie)aiiphaiie)carbonyl, (teteroaryi)earbonyl, and
(heteroara!ipha.tic)carbonyl, each of which, being defined herein and is. optionally substituted. Examples of amin gr ups Include alkyianiino, diai&yiamino, and aryiamino. When the term "amino" s not the terminal group {e,g., aikylearbcTfiyiam.m©)f: it is represented by -NRA-. RA has the same meaning as defined above.
OO *)] As used herein, an ry¥y group, used alone or as part of a larger moiety as in "aralfcyP, "araikoxy", or ^aryi xyalkyl" refers to monocyclic (e.g., phenyl):, bieyelie^e.g., IndenyL naphthalenyk teirahydronaphthyi, tetrahydroinden i), and tricyclic (e.g., finorenyl tetraliydro&norenyi or tetrahydroanthracenyl, anthracenyi) ring systems m which the monocyclic rin system is aromatic or at least one of the rings in a bicyclic or tricyclic ring system is aromatic. The bicyclic and tricyclic groups include benzofused 2- to 3-membered carbocyclic rings. For example, a ben ofused group includes phenyl fused with two or mor Q-s carboeycHe moieties. An aryi is optionally substituted with one or more substituents, such as aliphatic (e.g.. alkyl, alkenyl, or aikynyl), cycioaiiphatic, (eyeioaliphaticialipbaiic.. heierocyc!oaHphatie, (heteiOcycioaliphaticjaiiphatie, aryi heteroaryk aikoxy,
(cycioaliphaticjoxy, (heterocycloalipbatie)oxy aryioxy. heteroaryioxy. (araJipbatie)oxy, (heteroaraliphatic)oxy, aroyi, heteroaroyi, anu*no,.oxo (on a non-aromatic carbocyclic ring of a benzofused bicyefic or tricyclic aryl). nitro, carboxy, amidp; aeyl (e.g., aliphatieearbonyl, (cycloaiiphatic)carbonyl, ((cycioaiiphatic)aiiphaiic)earbonyl, (araliphaticicarbonyl,
(heterocycloaiiphaiicjcarbonybfihetero or
(heieroaraliphatic)carbonyl:), suHbnyi (e.g.. aiiphaiie-SOj- or annno-SOs-i siilflnyl (eg.. aiiphatic~S(<))~ or cycloaliphatic-S(O)-), su!fanyt (e.g., allphatic-S-k cyano, halo, hydroxy, mercapto,, sulfbxy, urea, thiourea, sulfamoyl.. snilarnide, .and carbamoyl Alternatively, an aryi can. be unsubstituted..
0020] Non-limiting examples of substituted ary!s include haloaryl (e.g., mono-, di- (such as /¾/is!-dihaloa:ryl}, or (trihalo}aryi). (carhQxy)aryl (e.g., (a!koxycarbonyl}aryl,
((aralkyl)carbonyloxy)aryl, or (alkoxyearbonyl)aryl), (amido)aryl (eg., (aminocarbonyl)aryk (((a{kyiamino.)alkyUarBmocarbon.yl)aryl> (ajkylcarhonyl)aminoaryt, (aryiaminocarbonyl)aryl, or (((heteroaryi)amino)carbonyl)aryl), amtnoaryl (e.g.. ((alkyIsitll nyl)amino)aryi or
((dialkyl)amino)aryl}, (eyanoafkyl}aryi. (alkoxy aryl, (sulfamoyl)aryl (e.g.,
(aminosuIi ny]}ary ), (alkylsulfonyjjary (cyano}aryl ihydroxyalkyl)aryL
■((alkosy)al:k lj r l (hydroxy)aryL ((carboxy}alkyi)aryk (((dialkyt)amino}alkyl)aryl, (nitroalkyl)aryf (((alkyls dfo^
((alkyisiiltbnyl)alkyl)aryl, (cyanoalkyi)aryl, (hydiOxyalkyl)aryh (aikylcarbony!)aryL
.alkylaryl, ( ril¾loalkyl}aiyk ^
aminoaryL and (;?i-(beterocycioaliphatk )-o-(aiky !))ary [,. [0002t] As used herein, an "araliphaUe" group, such as "aralkyl " refers to an aliphatic group. (e.g., a M alkyl group) that is substituted with an ary! group. Aliphatic,. aikyL and aryl are defined herein. An example of araiiphatie such as an aralkyl group is benzyl.
[00022] As used herein, a "'aralkyT group refers to an alkyl group ( e.g., a Cj.4 alkyl group) that is substituted, with an aryl group. Both alkyl and ary! have been 'defined above. An example of an aralkyl group is benzyl. An aralkyl is optionally substituted with one or more .subsiituents such as- .aliphatic (e.g., substituted or mrsubsiituted alk l. alkcnyl, or alkyriyl, including carboxya!ky!, hydroxyalkyl, or haloalkyl, such as tri'flitoromethyl}, cye!oaliphatic (e.g., substituted or unsubsiituted eycloalkyl or eyeloaikeny!),
(cy oalkyl)alkyL heterocycioalkyl (heter cyel0a!kyl)ai:kyls aryl, heteroaryl aikoxy, cycloalky!oxy, h^lerocyclcaikyJoxy, aryloxy, heieroary! xy, araikyloxy, heteroaralkyloxy, aroyk heteroaroyl, nttro, carhoxy, alkoxyearbonyl, aiky!earhonyloxy, ami do, (e.g.,
aminoearbonyl, a kylcarbooyiamino. cyckm!kylearbonylamino,
(cycloalky!alkyljearbonyianiino. aryiearbonylainino, araikylearhonylaniino,
(heieroeye!oaikyi}ea!'bonylamir!o. (heterocyeloalkyialkyi)earbonyiamino,
heteroarylcarbonyiamino, or heieroaralkylcarbpnylamino), cyano. halo, hydroxy, acyi, mercapto, aikylsulfanyL suifoxy. urea, thiourea, suliamoy!, sulfkmide, οκο,. and carbamo l
[00023] As used herein, a "bicycHc ring system" includes S- to 12- (e.g.. 9, 10, or 1 1) membered structures that, form two rings, wherein the two rings have at least one atom in common (e.g., 2 -atoms in common). Sieve lie ring systems include bieyeloa!iphatics (e.g., hicycloa!kyl or bicycioa! keny l}, bicycloheieroaliphaties, bieyelie ary is, and bie ehc heteroaryls.
[00024] As used herein, a "cycloaliphauc" .group encompasses a "cyctoslkyl" group and a "cyctoalkenyl" group, each of which being optionally substituted as set forth below, [00025] As used herein, a ^eycloalkyl" group refers to a saturated carboeyclic motto- or bieyclic (fused or bridged) ring of 3-1:0 (e.g., 5-10) carbon atoms. Examples of eycloalkyl group include eyelopropyl, cyclobutyk cyc!openty!., eyciohexyl, eyeloheptyk adamantyk norboniy cubyl, oeta.hydro-indenyl, decahydro-naphthvi bicyefoj3.2.1 ]ociyl,
bieyelo 2.2.2]octyl, bicyclop.3. i jrranyL bieyel:o[3.3.2..]decyi. b cycloP^ JJ et :!., adamantyk azacycloalkyl, and ((amin:Ocarbonyl)eycU>aSkyl}cyc.k:)alkyl< A "cyeloa!kenyP group, as used herein, refers to a non -aroma tic earboeyclic ring: of 3-10 (e.g., 4.-8) -carbon atoms having one or more double bonds. Examples of cycloalkenyl groups include eyelopentenyl, 1.4- cyc!ohexa-di-enyf, eyclohep enyl. eyclooctenyl, hexahydro-indenyL oetalxydro-naphthyk eyelohexenyi eyelopentenyl, bicyclo 2.2.2}octenyl, and bieyclo 3«3.1 jnonenyl, A eycloalkyl or cycloalkenyi group can be o tionally substituted with one -or more substituents such as aliphatic (e.g., aikyi, alkenyl, or lkynyl), eycloaiiphatie, (eycloaiiphatie) .aliphatic, heteiOcyeloaliphatie, (heterocycioa!iphatk) aliphatic, aryi, heteroaryl, alkoxy,
(cycioaliphatic)oxy, (heterocycloaliphatk)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (beteroai'al!phatic)oxy, aroy.l. hetcroaroyl, ..amino, amido (e.g., { aliphatic )carbo.uyl mino.(cyeioaliphatie)earboivylaTnin. v ((cycloaiiphatie )aliph.a†ic)earboTiy arnino
(aryikarbonylamrno, (araiiphatic)carbonyiamino, helerocycioaliphaiic)carbonylamino, ((het rpcycloaliphatk a!iphatk)carbonylamino, (heteix aryi)carixn.iylamiiio, or
(fheterDaraliphatkJearboii lamirjoJ, nitro, earboxy £e,g., HOOC- alkoxyearhonyl. or alkylearhonyloxy), ac l (e.g., (eyc!oaliphatic)carbonyl, (cycloaiipbatic) aiiphatic)oarboiiyi (aral iphati e)c arbonyi , eterocyc loal iphatic k arbony 1,
((heteroeycioalip alic}aiiphaiic)carboriyl, or (heteroaMlipbaticicarbonyl}, eyano, halo, hydroxy, mercapto, sulfcm l (e.g., alkyl-SO?-, or aryl-SOx-), sulilnyl (e.g„ aikyi-S{0}-), solfanyl (e.g., alkyi-S-), sulfoxy, urea, thiourea,, suifamoyi,. sutiaraide, oxo. and carbamoyl.
[00026] As used herein, "'cyclic moiety"' includes cycloaiipbatic, heteroeycloalipha ic, aryi,. or heteroaryl, each of which has been defi ned previously,
[00027] As used herein, the term 'lieterocyeioaliphatk" encompasses a
heterocyeloalkyl group and a heteroeycloaikeny 1 group, each of which being optionally substituted as set forth: below,
100028] As used herein, a
Figure imgf000012_0001
refers to a 3-3 G nrembered BT BO- or bky!k (fused or bridged.) (e.g., 5- to 1.0-membered mono- or bkycik) saturated ring structure, in which one or more of the ring atoms is: heteroatom (e.g., N, 0, S, or combinations thereof). Examples of a heterocycloalkyl group include piperidyi, piperazyl. teirahydropyranyi, tetr hyd.ro lory I, 1 ,4-di.oxoianyL ,4-diihi.anyf L3~dioxolanyl, oxazolidyl, isoxazoiidy!, mor holra &iom ^holyl OCtahydrobenzoimyl, oeiahydroehromenyl, oeiahydrothiochromeny!, octahydroindolyi, octahydropyrindinyl, decahydroc ui oliny'
Figure imgf000012_0002
bicyc!o[3.2.I]octyi, and 2,6-dioxa~trky op.3.1 .0J,']nonyl. A monocyclic heterocyeloaiky! group can- be fused with a phenyl moiety such as tetrahydroisoquinoiine. A
"heteroeycioalkenyf' group, as used herein, refers to a mono- or bkylic (e.g., 5- to 10- membered mono- or bk el ) non-aromatic ring structure having one or more double bonds, and wherein, one or more of the ring atoms is a heteroatom (e,g,5 N, (), or S), Monocyclic and bicydobete oaliphaiics are numbered according to standard chemica! nomenclature. [00029] A eterocycl.oalk ! or heteroeyekaikeayl. group can. be optionally substituted with one or m re sabstituenis such as. aliphatic (e.g., alkyk alkenyl, or alkyiiyl),
eyeloalipkUic. :(cycIoaliphaUc)aHphatie. heierocycloaiiphatic, (heterocycioalipl icjalipbatic, aryL heteroar l, a!koxy, (cycioalsphatic)osy, (beierocycloa]ipbatic)os.y, aryloxy,
heteroafy!oxy,
Figure imgf000013_0001
(e.g., (aliphaiie)earbQny!amino, (cyc aliphaticiearbojiylanunQ,. (eycloaliphatic)
aiiphatic)carbonylamino. (aryl)earbon:y!amino,: (aral!p.hatic)carbpriylarain(5;
(het rocycloaiiphatic)carbonylai ino, ((heterocycloaiiphatic) aii;phaiie)eatlx>nylaniino, (heteroaryljcarbonylanibio. or (heleroara!iphatie)carboriy]a iino), nitro. carbo y (e.g..
i:!OOC~. alko ycarboHvL or aiiylcarbonyioxy}, acyl (e.g., (cycloaliphatie)carbonyi.,
((cyciosliphatie) ali.phatic)c&rbouyL (araHphatiejcarboriy!, -.(hctemcyck>aliphatk;)carbonyl- ((heteiXJc clo liphali-CjaiJi haiio^aAon l, or (heteroaraliphatic)earboiTvi}:. nitro. cya.no, halo, hydroxy, mercapto, sulfenyJ (e.g.5 alkylsultonyi or arylsuli inyl);. stili ny 1 (e.g., a!ky!sulfinyi). sulfanyl (e.g., alkylsuiianyi), sulfoxy, urea, thiourea, sulfanioyh sutfamide, oxo, and carbamoyl
|O0O30] As used herein,, a "heteroary group refers to a monocyclic, bicycl c. or tricyclic ring system ha ving 4 to 15 ring atoms, wherein: one or more of the ring atoms is a heteroatom (e.g., N, ().. S, or combinations thereof) and in which the monocyclic ring system is .aromatic or at least one of the rings in. the bicyclic or tricyclic ring systems is aromatic, A heteroaryl group includes a benzol used ring system, having 2 to 3 rings. For example, a benzofused group includes benzo fused wi h one or two 4 to 8 merabered.
heteroeycloaiiphatic moieties (e.g.. indolizy!, indolyl LsoindoiyL 3H-indoIyl, indoiinyl.
ben¾ [6]:i¾ryl, benzof/fjthhTOhenyi qninolinyl or isoquinoHnyl). Some examples of heteroaryl are azetidinyl. pyridyl, 1 H-indazolyl, furyl pyrroiyi, thienyl, ihiazoiyi, oxazolyt imidazo!yl, tetrazolyi, benzofuryl, isoquinoiinyb benzthiazoiyl, xantheue, thioxanthene. phenoihiazine, dihydroindole, benzo 3]dioxole, berizo[b furyl, benzo b]thiophenyi, indazoiyl benzimidazolyl. benzthiazo!y!, puryl, einnolyi quinoiyl quinazolyl, phthalazyl, qninazolyk qulnoxalyi isoquinoly!. 411- ui.n.oiizyi benzo-l ,2,5-tMadiazolyk and 1 ,8- napblhyridyl.
{00031] Without linn lation. monocyclic heteroaryls include .fur l, thiophenyl, 2,11- pyrroiyi, pyrroiyi, oxasiolyl. thazolyi, imidazoiyi, pyrazolyi isoxazolyl, isothiazolyl, 1 ,3,4- thiadiazo!yi, 2H~pyranyl, 4-B-pranyl, pyridyl, pyridazyl. pyrimidyL pyrazoiyl, pyrazyl, and 1.3,.5-triazyl. Monocyclic heteroaryls are . numbered according to standard chemical nomenclature., [00032] Without limitation, bicyclie heteroaryls include tadelizyl, mdoiy isoindolyi, 3ii~md lyL mdolkyk benzcsfi i:u:r l beozo /j thiopheayl} qumofinyl, isoquinoiinyl, indoiizyk isomdelvl, indo!yi, ben¾ojd]i¾ryL bexo[/?]thiophenyk indazolyl, benzb dazyk benzthiaaaiyh purinyk 4H-quinol.feylJ quinolyl, isoquinolyk einnolyk phtbalazyk qivhwq!yl, qu oxalyi, 1.8-naphtbyridyk and pieridvl. Bicyclie heteroaryls are numbered, according, to standard chemical nomenclature.
[00033] A beteroarv I Is optionally substituted with one or more substituents such as aliphatic (e.g., alky I, alkenyl or a!kynyl), cyeloaliphatk, icycioaliphatic)aIipb.atieT beterocycloaiipbatic, (heterocycloaUphatie}aHphatic. aryk heteroaryl alkoxy,
(cye}oaliphatie}oxy, iheferocycloaUpha ie)oxy. aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaialiphatie)oxy. aroyl heteroaroyl amino, oxo (on a now~amn atie earbocyelic or heterocyclic ring of a bicyclie or tricyclic heteroaryl), earbox , amido. acyl (e.g.,
alipbadeearbonyi, .ieycloaliphatiejcarbonyi, {{cyc ai:ipbaiic)aliphatic)carbo:Hy!,
farahpbaiie)carboiiyl, (he eroeye!.oaliphatic)carbonyL
((heferoe ^^ or (heteroaraliphaticicarbQTjyl), sulfdriyl (e,g,, aliphat ί es i f ny I or a inosulftmyl), .sulfmyl. (e.g., alipbatiesulilny!), sulfanyi (e.g., allphatiesuli nyt), nitro, eyano, halo, hydroxy, mercapto, suSfoxy, urea, thiourea, siilfarttoyi, sulfaraide, and carbamoyl Alternatively, a heteroaryl can be unsubstituted.
10003 1 Non-limiting examples of substi toted heteroaryk include (halo)heieroaryi (e.g., mono- and di-(halo)heteroaryt), (carboKy)hcieroary! (e.g., (alkoxycarbonyi)hcieroary!), eyanoheteroaryi, mimo'heteroaiyl. (e.g.. ((alkyisuli¾iwI}amin:o)beteroaryl
and((djalkyi)amino)beteroaryI), (amidotheteroaryl (e.g., aminocarbonylbeteroaryi
((alkykaTbonyl)amiBo)3ieteroaryl, ((((alkyi ¾mIno}aikyI}aminocarbonyl}beieroary!,
(((heteroaryl)amino)earbonyl)lieteroaryL ((heterocycloailphatic)carbonyl)heteroaryL or ((aikylcarboriyI)arrii:!i0)beteiOaryl), (cyan alky{)heteroaryk (alkoxy)heteroaryl
(suliamoY!)beteroaryl (e.g., (an)inosn!fonyl)beteroary]), (sulibnyl)heteroaryi ((e.g..
(atkylsuifonyl heteroaryl), (hydrpxyaikyl)¼eteroa:ryk (alkoxyalkyl)heteroaryk
(hydroxy;}heteroaryk ((carboxy)a!ky] )keteroaryL {((dialkyl)arnin0}aiky1)li.eteroaryl,
(beierocycloalipbaiic)heteroaryl? (eycloaiiphaiic)keteroaryk (nitroalky!)heieroaryl,
(((a!ky!suifonyI)amino)alkyl)heteiOaryk ((alkY!st^lbiryl)alkyl)heteroaryL
(cyanoaiky])heieroaryk (aeyi)he£eroary! (e.g., falkylcarbo«yl)heteroaryl}, (alkyl)heteroaryi and (haioalkyl)heteroaryl (e.g., , tribaioaik !heieroaryl), (00035} As used herein. ';¾eteroaraHphatic* (such as a heteroaraik l group) refers to an aliphatic group (e.g., a C alkyl group) ihat'is substituted with, a heteroaryl group. Aliphatic, alkyl, and heteroaryl. have been defined above.
(00036} As used herein, a. "heteroaralkyr group refers to an alkyl group (e.g., a CM alky] .group), that is substituted with, a ..he ternary! group. Both "alkyl" and ¾¾eteroaryP have been defined above. A heteroaralkyl is optionally substituted with one or more substituenis, such as .alkyl (including carboxyaikyh hydroxyalkyi and hatoalkyl such as triiluoromethvl). alkenyi a kynyi, eyctoalkyk (eyeloaSkyi)alkyl, heteroeycloalkyl, (he eroeycloalkyl)alkyl, aryl, heieroaryl, alkoxy, cycloalkyioxy, heterocycloaikyloxy, aryloxy, heteroaryloxy, aralkyjoxy, heteroaralk loxy. aroyl, heteroaroyl. tiitro, carhoxy, alkoxyearhcmyi,
alk learbonyloxy, aniinocarhonyk alkylcarbonyiarsiino, cycloalkylcarbonylamino,
(eyel.oalky1alkyi}earbonylam!.nO arylcarbonylamrno, aralky!carbonyla ino,
heierQcyc!oalkyl)carbony!amino, (heterocyeloalkyiaikyOearbonylamino,
heieroarylearbonyianiino, heteroaralkyicarbonyl ffio, cyano, halo, hydroxy, acyl mereapio, alkylsid&uyi sulfbxy, urea, thiourea, sulfamoyk sulfaraide, oxo , and carbamoyl,
100037] As used: herein, an 4iaey!"' grou refers to a forniyi grou or RA-C(Q (such as alkyl-C(O.K also referred to as *'alkylcarbonyr>- wherein. R: and alkyl have been defined previously. Acetyl and pivaloyl are examples of acyl groups.
[00038] As used herein, an "aroyP or 'lieteroaro Γ refers to an ary kC(O)- o a heteroaryl-C(O)-, The aryl and heteroaryl portion of the aroyl or heteroaroyl axe opiionaily substituted, as previously defined..
{00039] As used herein, an ''alkox ' group refers to an alkyl-O- group, wherein, alkyl has bee defined previ usly,
{'00040] As used herein, a "carbamoyl'5 grou refers to a group having the structure -O-
CQ-NR.SRY or ~NRx-CO-0~R¾, wherein Rx and RY have been defined above, and R* can he aliphatic, aryl, araliphatic, heterocyeloaJi hatic, heteroaryl. or heteroaraiiphatie.
[00041] As used herein, ;'carboxy^ group refers to -CQOH, -COOR , -OC(C)}B, or -
OC(0)Rx when used teruunaily and ~GC(0)~ or -€(0)0- when used internally.
[00042] As used herein, a "haloalinhatie" group refers to an aliphatic group substituted with 1 -3 halogens. For example, the term haloaikyl includes the gr u ~C .¾,
100043] As used herein, a "mercapto" group refers to -Sl i .
100044] As used herein, a "suiter' gr up refers to -S(¾H or -S(¾RX when used terminally and ~S;({¾- when used internally. |0ΟΘ4δ] As used herein, a "sulikmi-de-' group refers to the structure ~NRA~S(0)2- N V Z when used terminally and - X-$|0)2- R ~ when used internally, wherein R , R* , and R"' have been defined above.
[00046] As used herein, a "sulfonamide" group refers to the structure -Si O}2-NRAK' or -NRx-S(0)2~R when used terminally and -SiO 2- Rx- or -NRX -S(C))r when used
Internally, wherein ilx, R and R'" hav been defined above.
|0β047] As used herein, a '^ulfanyp group refers to -S-Rx when used terminally and - S- when used internally, · wherein RA has been defined above. Examples of sulfanyl include al'ipiiatie-S-, cycfoaliphatic-S-, and aryl-S-, or the like.
0O 48| As used herein a suifinyl" grou refers to -S(0)~RA when used terminally and - S(0)- when used internally, wherein Rx has heen defined above. Exeniple of sulfmyl groups include aliphatic-SCO)-, aryi-S(O -, (cyeloaliphalic(aliphatic)} -S(OK cycloalky 1- :S(Q)-, heteroeycioaliphaiie-SiC))--. and heteroaryi-S(0)~, or the like.
|0Q049'j As used herein, a "sulfony Γ group refers to~S(Q}2-R' when used terminall and - S(0) - when used internally, wherein RA has been deilned above. Exemplary sulfonyl groups include aliphatic-SCO};-, aryl-S(<¾rf- {{eycloaiiphatie(aliphatic):)~S O¾-, eyeloaliphatie- (0)2-, heteroeycloal.ipba ie-S(0)r. heterpai l-S(0¾>-f and
(eycloallphatic(ainido(a].iphatie))}-S;{0)2-, or the like.
1.00050] used herein, a "sulf xy"5 group refers to -Q-SO-R or ~SO-0~RX when used terminally and -O-S(O)- or -S'(0}-0- when used internally, wherein R:x has been defined above.
[00051} As used herein, a "halogen" or "h l '" group refers to fluorine, chlorine, bromine, or iodine:.
[0.0052} As used herein, an "alko ycarbonyF' group, which is encompassed b "carboxy," used alone or in -combination wi th another group, refers to a group such as alkyi-Q~C(QH
}0O0$3| As used herein, an "afkoxyalkyf* group refers to an alkyl group such m. alkyl-O- alkyk wherein alkyl has been defined above.
[00054] As used herein, a "carbonyr* group refer to -C(0}-.
[00055] As used herein, an ¾χ group refers to; ::::0.
(00056] As used herein, an "aminoalkyl" group refers to the structure {Rx 2 -alk k
[00057] As used herein, a "eyanoalkyl group, refers to the structure {NC)-alkyl-.
[00058} As used herein, "are grou refers to the structure -N X-C()-MR¾ and a "thiourea" group refers t the structure -NRX-€S~NR¾Z when used terminall and -KRS- CO-NR '~ or -NRX-CS-MRY- when used internally, wherein Rx, RY, and Rz have been defined above.
[0( 059] As used herein, a "guanidine" group refers to the structure N^C(N(RXRY) N(RXRY) or - iR¾=NRx)NR¾v, wherein R.s and R¾ have been defined above,
(00060] As \ised herein, an "amid no" grou refers to the structure -C:::fHRx)N{RxR ).
wherein x and R have been defined above.
( 061 As used herein, the term "vicinal" refers to the placement of substituents on a grou : that includes two or more carbon atoms, where n, the substituents are attached to adjacent carbon atoms.
f00062| As used herein, the term "geroinaP* refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to the same carbon atom,
(00063] As used herein, the terms "terminally" and 'Internally" refer t the location of a group within a substitueni. A group is terminal when the group is present at the end of the substitueni and not further bonded to the rest of the chemical structure. Caybox.yalk.yL i.e.. RxO(0)C~al.kyl, is an example of a earboxy group used terminally, A group is internal when it is not terminal Alkylcarboxy (e.g., a!kyl-C(O)-C)- or alkyl-O-C(O)-) and aikyiearboxyary!
Figure imgf000017_0001
internally.
00064J As used herein, "cyclic" group includes mono-, hi-, and tri-cyciic ring systems, such as cycloaliphaiic. heteroeyeloaHphatic, aryl. and. heteroaryl. each of which has been defined: above.
100065] As used herein, a "bridged hieyclie ring system"' refers to a bicyclie
hetcroeyelica!ipahtic ring system or bicyclie cycloaliphaiic ring system in. which, the rings are bridged. Examples of bridged bicyclie ring systems include, but. re not limited to, adamantanyL norbornanyl, bicyclo 3.2.1 fociyi bicycla[ .2:;2}dctyl- bicyclo[3.3.1 jnonyl btcyeIo 3,2.3]nonyL 2 >xabieycio 2.2.2'joctyL l-azabieyc!o[2.2.2JoctyK 3- azabkycjop.2:J]oetyl, and 2,6-dioxa-iriCyclo[3,3.1.O^jnonyi A bridged bicyclie ring system can be optionally substituted with one or more substituent such as alkyl (including carboxyaikyL bydroxyalky!, and haloa!kyi such as trii'luoromethyl),: alkenyi, alkynyl.
cyc.loalkyL (cyck alkyl)aiky!, h.eierocycioalkyl, ~het.eroeycIoalkyl)aIfcyl, aryl, heteroaryl alkoxy, eyeloalkyloxy, heterocycloaikyioxy. aryloxy, heteroaryloxy, araikyloxy,
heteroaralkyloxy, aroyf heteroaroyl, nit.ro, earboxy, aikoxycarbonyl, alkylearbony!oxy, ammoearbonyl aikylcarbonylaraino, eycloaikylearboBylamino, (cyc|oalkylai.k l)carbottyiaimno, arylcarbonyia ino, aralkylcarbonylanjine.
(heierocyc!oalky carbonyiammo:, ^ter0cyel alKyl¾&yl)carbonyIarai»G,
heterDarylcarbonylamino, fecteroaraikyteartoylamm , cyano, halo, hydroxy, aeyl, mercaptp, alkyJsuifanyl sulfbxy, urea, thiourea, sulfamoyh sulfa ide. oxo, and carbamoyl.
[90066] As used herein, an "aliphatic chain" refers to branched or straight aliphatic group (e,g., alkyl groups, alkenyl. groups, or alkynyl groups). A. straight aliphatic chain has the structure -(€¾)*-, where v is 1 -6, A branched aliphatic chain is: a straight aliphatic chain that is substituted with one or more aliphatic groups. A branched aliphatic chain has the structure -(CMQ y-, where y is 1.-6 and Q is hydrogen or an aliphatic group; however, Q shali be an aliphatic group in at least one instance. The term aliphatic chain includes alkyl chains, alkenyl chains, and alkynyl chains, where alkyl. alkenyl and alkynyl are defined above,
[00067] As used herein, the phrase "optionally substituted" is used interchangeabl wit the phrase "substituted or unsubstituted." As described herein, compounds of the in vention can optionally be substituted with one or more substituents; such as; are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. As described herein, the variables ¾, ¾, ?. and .¾., as well as other variables, encompass specific groups, such as alkyl and ary!. Unless otherwise noted, each of the specific groups for the variables R5,. ¾, ¾, and ¾,: and other variables contained therein can he optionally substituted with one or more substituents described herein. Each substituent of a specific group is further optionally substituted with. one- to three of halo, cyano, oxo, alkoxy. hydroxy, amino, nitro, aryl cye!oaliphatic, heierocyeloaliphatic, heieroaryl, haloalkyl. and alkyl. For instance, an alkyl group can be substituted with aikylsulianyl, and the alkylsultany] can be optionally substituted with one to three of halo, cyano, oxo. alkoxy. hydroxy, amino, nit.ro,. aryLhaloalk-yi, and -alkyl. As an additional example, the cyeloalkyl portion of a
(eycloaikyl)ca bonyiamino can be optionally substituted with one to three of halo, cyano, alkoxy. hydroxy, nitro, haloalkyl, and alkyl. When two alkoxy groups are bound to the same atom or adjacent atoms, the tw alkxoy groups can form a ring together with the atorn(s) to which they are bound.
(#08.68.) A used herein, the term "substituted/" whether preceded by the term optionally or not, refers to the replacement of hydrogen radicals in a gi en structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof Unless otherwise indicated, an optionally substituted group can have a substituent at each substifiuable position of the group, and when more than one position in any gi ven structure can. be substituted with more than one su ituent selected from a specified group, the subsiitueni can be either the same or different at every position. A ring snbstiluent, such as a heterocycloa!kyl, can be bound to another ring, suc as a cycloalkyl, to form a s iro-bioyclie rin system, le., both, rings share one common atom. Combinations of subsiituenis envisioned by this invention are those combinations thai result in the formation- of stable o chemicall feasible compounds.
{00069J As used herein, the phrase'stabl or chemically feasible" refers to compounds that are not substantially altered when subjected, to conditions to allow for their production, detection, and preterahly their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one .that is not substantiall altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week,
[00070] As used herein, the phrase "preparing enaMi vSe!eeiive.iy''> refers to asymmetric synthetic preparation of enantiomerica!ly-enriched compounds. This is further defined as the use of one or more techniques to prepare the desired compound in high enantiomeric excess (i.e., 60% or more). The techniques encompassed may include the use o chirai starting materials (e.g., -chirai pool synthesis), the -use of.chiral auxiliaries and chirai catalysts, and the. application of asymmetric induction,
{000711 As used herein, ^enantiomeric excess'" or ^e.e,,** refers to the optical purity of a compound.
[000721 As used herein, "encfa.'exo" refers to the ratio of e¾fo~iso.mers to exo-iso ers.
[00073] As used herein, '"enantiomeric ratio." or "e ," is. the. ratio of the percentage of one enantiomer in a mixture to that of the other,
jO0 74| As used herein, a "protecting group" is defined as a group that is introduced into a molecule to modify a functional group present in a molecule to prevent It from reacting in a subsequent chemical reaction and thus obtain chemoseleciivity. it is removed from the molecule at a later step, in the synthesis. For example, a carbobenzyloxy (Cbz) group can. replace the hydrogen on a amine to prevent it front reactin with an eieetrophile, then the. Cbz group can: be removed by hydrolysis in a later step.
[00075] Acid and amine protecting groups as used herein are: known: in the art (see, e.g., T.W. Greene & P.G.M Wutz, - 'Protective Groups in Organic Synthesis." .3** Edition, John Wiley & Sons, inc. (1999)), Examples of suitable protecting groups for acids include ttn- butoxy, benzyloxy, all ioxy, and inethoxyrnethoxy. Examples of suitable protecting groups for amines include 9-fi.tioreny.lmeth l carbamate, /er/ x«yf carbamate,, benzyl carbamate, irifiaoroaeeianiide, and p-teluenesuifonarnide; 007 ] As used herein, a "effective amount'' is defined a the amount required to. confer a tberapeiitic effect: on the treated patient and is typically determined based on age, surface area, weight and condition of the patient. The interrel ationship of dosages for animals and ■humans (based on mi Hi grants per meter squared o f body surface) is described by Preireieh et ah. Cancer Ciw &ther. Rep., 50: 219 ( i%6). Body surface area may be approximatel determined from height and weight of the patient. See, e.g.. Scientific 'Tables, eigy
Pharmaceuticals, Ardsiey, Hew York, 537 (1970}:. As used herein, "patient" refers to a mammal, including a human..
|O0O77| Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diasiereomeric, and geometric (or conformational)) tottns of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (Ej conformational isomers.. Therefore, single
stereochemical isomers as well as enantiomeric, diasiereomeric, and geometric (or eonformational) mixtures of the present compounds are wi thin the scope of the invention. Unless otherwise stated, , ll tautomeric forms of the compounds of the in vention are within the scope of the inveniion.
1000-78] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds thai differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the. replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 'C- or 14C-enriehed carbon, are within the scope of this invention. Such compounds are useful, for example* as analytical tools or probes in biological assays,
(00O79J As used herein, "E'DC" is l H3<hmethyiaminopropyl}~3-ethylearbodiimlde. "HOBf is 1 -hydroxybenzotriaEole,
Figure imgf000020_0001
"Cbsf is beuzyloxyearbonyi isDCM" is dichloromethane, and "Boc"' is k?ri"-butoxycarhonyl,
[00080] As used herein, "Hi N " stands for proton nuclear magnetic resonance, and *TLC* stands for thin layer chromatography.
Embodiments
100081] In one aspect, the invention provides processes and. intermediates for producing bicyclic derivatives of formula la or lb:
I S
Figure imgf000021_0001
la lb wnerem:
ring A is a C3.12 cycfoal phatie ring;
ring B is a G. s?. beteroeycioaHphatic ring containing an additional 0 to 2 heiero atoms, each independently selected from O, M, d that can be optionally substituted with 1 to 4 groups, each independentl selected from alkyl, halo, alkoxy, aryL and hydroxy!;
Ri is H or a protecting group: and
R? is H or C ι-ϊ2 aliphatic,
[00082] in one embodiment, ring A is a C3-6 cycloaliplmtic ring.
Figure imgf000021_0002
[00085] In another era bod iraent, ring A is eycIopfopyL
[00086] More particularly., ring A is -dimeth leyclopropyL
(00087] More particularly, ring. A is
Figure imgf000021_0003
[00088] in one embodiment, ring B is aryL
[00089] More particularly, ring B is phenyl. 100 901 More: particularly, ring B is:
Figure imgf000022_0001
00091- 1 In one embodiment, .ring B is a S-raembered: heterocyclic ring.
[00092] In one embodiment, nne B
Figure imgf000022_0002
{000931 In another embodiment, ring B is substituted with a aryi ring optionally substituted with I to 4 groups, each independently selected .firom lkyl, halo, alkoxy, and hydroxy L
1000941 More parti
Figure imgf000022_0003
f 095] In one embodiment, j is H.
f 00096 | in another embodiment, 5 is a protecting group.
100097] Mo-re' particularly, t is fer/-batyl: carbamate (Boc)
{00098f in one embodiment, R2 is ii.
[00099 j In another embodiment, R2 &.€¾.12.aliphatic,
[OOMOOJ More particularly, 2 i C^ alkyS.
[06010! j In one embodiment, .¾ is methyl ethyl, ff-propy!, im- ISO- b tyl, -w-peuty or i.w-penty;L
{0001021 More particularly, R2 is fto-butyl
{0001031 in another embodiment, R2 is /ert- uiyl. 1000104] In a further embodiment, ¾ is a c eloabphatic ring.
[08010$] Another aspect relates to a process for preparing enaniioselectlvely compounds of formula. la or lb over com ounds of formi as ~ lb:
Figure imgf000023_0001
If Ig lb
[000106] The process und of fomniia Ha or lib:
Figure imgf000023_0002
11a lib
wherein R;!l is proteciing group, und of formula III:
Figure imgf000023_0003
01 wherein R; and R4 are each independently a protecting group, C .n aliphatic, or a cyclic group selected from the group consisting of cyeloallphatic, hetcrocveioaiiphatie. aryh and heteroaryi
J000l07|ln. one embodiment, Ris is i r/~butyl carbamate (Boc .
[GDOlO&JIn one embodiment, the step of carboxyiating a . compound of formula II is in the presence of a compound of .formula Ilia:
Figure imgf000024_0001
Ola
fOO lOS] In another embodiment, the step of carboxyiating a compound of formula 0 is in the presence of a compound of .fo
Figure imgf000024_0002
■Mb
fOOOliOJ In another- embodiment, the step of carboxyiating a compound of tbmru!a Ills in the presence of a compound of
Figure imgf000024_0003
Me
[0001 Π f in another embodiment, the step of carboxyiating a compound of formula I ! is in the presence of a compound of formula. Hid;
Figure imgf000025_0001
[ΟΘ'ΘΊ 1 ] In another embod ment, the step of carboxylating a compound of formula II is n the presence of .a compound of formula Hie:
Figure imgf000025_0002
ίΠ-e
fOOOJ 13Ι ΪΪ1 one embodiment ¾ is C n aliphatic,
[000114] More particularly, 1¾ is C . unbranched aSkyl.
[000115] In one embodiment, l t is CM branched alky!
[000116} In another embodiment, ,| is Cw branched a!kyL substituted with a cyclic group.
[000117] More particularly. R4ls CM. branched alkyl, substituted with a phenyl group.
[000118] in one embodiment iii s a cyclic group.
[000119] More particularly. !¾ is a bkyclie group.
[000120] In one embodiment, the arboxylaiion step comprises treating compound of formula Ha or Ob with carbon dioxide and a lithi um base in the presence of an aproite solvent.
{000121] In on embodimen the aprotic solvent is selected from the group consisting of toluene, ethyl aeetate? benzene, and methyl te'i-butyl ether (MTBE).
[0001.22] More particularly, the aprotic solvent is MTBE.
[000123] In one embodiment, the lithium base is .¾¾' >iityl lithium.
[000.124] in one embodiment the process of the present invention gives rise to a mixture of products including H a (exo% 1-3 (ex& 1-2: (endo), and 14 (emfo),
[006:125] In one embodiment, after carboxylation. the combined . "weight percent in a mixture comprising eonvpotmds of formula la and .(the e:¾:o-isomers) and compounds of ormula Ic and le (the endo4somtti):is 100 weight percent, [000126] In one embodiment, the ratio of the eombined weight pereent of ia and id (exo- isomers): to: thai of le and le ( do-iso ets) is at least 60 to 40.
[0001271 More particularly, the ex&fendo ratio is at feast 80 to 20.
[000128f More particularly,, the exafemh ratio is at least 90 to 10.
[006129] More particularly, the exol'endo ratio is at least 95 to 5.
[000130] More particularly, the exolendo mxo ts at leas 97 to ,
[ΟΟ01.31| 1η one embodiment, the process further comprises the. step of removing a portion o the compounds of formula Ic and/or le f om Che produet mixture.
[000:132] More particularly, the compounds .of formula le and/or k are removed by crystallizing the compound of formula la or lb.
[000133] In another embodiment, the compounds of formula Le and/or le are removed by recrysiailrang the -compound of formula ia or lb.
000134] In one embodiment the ratio of the weight percent of la to Id is at leas 60 to 40. $00135] More particularly, the ratio of the weight percent of la to Id is at least 80 to 20, [0001 M] More particularly, the ratio of the weight percent o la to Id is at least 90 to 10, [000137) More particularly, the ratio of the weight percent of la to Id is at. least 95 to 5.. 000138] More particularly, he ratio of the weight percent of la to Id is at least 99 to 1 f 000139] More particularly, the ratio of the weight percent of la. to Id is at least 99.6 to 0,4. 1000140] More particularly 1, the ratio of the weight percent of la to id is at least 1 0 to 0, [000141 ] Another aspect is d a compound of formula 1 :
Figure imgf000026_0001
10
wherein ¾ is 1:1, C^iZ aliphatic, or a protecting group, and Z? is H or a protecting . group, comprising the steps of
a. forming. a 2-arsiori of a compound of formula ila:
Figure imgf000027_0001
I la
wherein Rja nd ring A are defined above, in the presence of a compound of formula 11;
Figure imgf000027_0002
III
wherein R.¾ and ¾ are defined above;
treating the 2-anion of step a with carbon dioxide to produce
enaniioseleedwly a compound of formula la; and
reacting the compound of formula la with a compound of formula 26:
ZyHH COOH ^
26
wherein ¾ ¾ a protecting group.
{000142} in one embodiment, the compound. of formula II ί is a compound of formula Ola.ίΗΗίί 43) Irs another embodiment, the com ound of formula HI is a compound of forraula Illb. { O0144| In one embodiment,: the compound of formula 26 is the compound of formula 26-a:
Figure imgf000027_0003
(0001 5J In. another embodiment the compound of onftuk'26. is the compound: of formula 26-b:
¾-NH' "COOH
26-b
: 46] One aspect is directed to a compound of formula la-t made by the processes disclosed, herein:
Figure imgf000028_0001
£11001 7f Another aspect relates to a compound of formul ia-2 made by the processes disclosed herein:
Figure imgf000028_0002
ia-2
I Another aspect is directed to a .compound, of formula la-3 made by the processe disclosed herein:
Figure imgf000028_0003
fa-3
100 149] Another ispeci relates to a: compound of formula la-4 made by the processes
Figure imgf000029_0001
Ia~4
[000.150] One aspect is directed to a compound of formula 10-a made by the processes disclosed: herein:
Figure imgf000029_0002
10-a
1000151 ] In one embodiment the compound of formula 10 is a compound of i rmul I0-af wherein∑ s Hf and ¾is /erz-hutyl.
1000152] Another aspect relates to a compound of formula 10-b made y the processes disclosed herein:
Figure imgf000029_0003
0-b
[000.153] Another aspect is directed, io a compound of formula 10-e made by the processes disclosed herein:
Figure imgf000029_0004
10-c
[0001541 In one embodiment, the compound of formula 10 is a compound of formula 10-b, wherein Z? is H, and >is im-butYl. 000155] Another aspect relates to a compound of formula 10-d made by the processes
Figure imgf000030_0001
Processes and Intermediate ?;
[000156] i one aspect, the invention provides: a process and intermediates for preparing a compound of formula. la as outlined in Scheme i, wherein Rj, R¾ Ri, R4, and rin A are previously defined.
Scheme 1
Figure imgf000030_0002
|000l57j Carboxylation of the compound of formula Ilk is: achieved by first forming a 2- anion of ibrmula Ha in the presence of a compound of formula IIL For formation of similar anions, see, ,g„ Daniel. J. Pippel, et, al, J. Org: O em., 199 , 63. 2; Donald J. Gallagher et at, J. Org. ahem., 1995, 60(22), 7092-7093: Shawn T. Kerrick. et al, <l Am. Chem, Sac. 199-1 , Π3.(25), 9708-9710; Donald .1. Gallagher et al., J Org. Chem. , 1995, 60(25), 8 MS- SI 54; and Peter Beak et al, J. Am. Cham- Soc 1 94, 1 Ϊ6(8), 3231-3239. The 2-anion of formula Ha (not. shown in Scheme 1} is prepared by treatment of compound of formula. I la with a strong lithium base (e.g., ,vec-butyiliihiura or isopmpylliihium in a. suitable aprotic solvent (e.g., MTBE, diethyletlier, or toluene) in the presence of a compound of formula III. f 000158] An optically acti ve compound of formul HI can induce enantioselective earboxylation to give a product having an enantiomeric excess (e.e.) of from abo t 10% t about 95% (see, e.g.. Beak c d., J. Org. Chem., 1 95, 60. 8148-S154 . In. the presence of formula IIL a compound of ibrmula Ila can be treated with carbon dioxide to give a mixture of exo ndo compounds, wherein the ex.o enda ratio is 60 to 40, 80 to 20, 90 to 1 (L 95 to 5, or greater than 98 to 2. [000159] Referring to Scheme I. a compound of formula 11a, wherein R.†a is, e.g.. ieri- butoxyearbanyl (Bae). is prepared. using known methods. See, e.g.. T..W. Greene and P. G. M uts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley and Sons, Inc. (1999).
[000160) Compounds of formula HI can be prepared as shown in Scheme II A.
Figure imgf000031_0001
[000161] When R5 and R,f. are the same, compounds of formul 01 ca be prepared by condensation of a substituted piperdone derivative with formaldehyde or a formaldehyde equivalent,
jOOOI 62] Alternatively, compounds- of formula III can be prepared as sho wn in Scheme IIB.
Figure imgf000031_0002
[000 31 When Rj and R4 are not the same, the commercially available diproteeted amine can be used to prepare compounds of formula III via a sequence of selective deproteciion reactions and other transforations known to the skilled artisan.
O! 641 Scheme H I depicts the reaction of a compound of form ula -26- with a compound of formula la to form a compound of fo-rmuia '28, wherein R? is defined' above. Scheme !
Figure imgf000032_0001
[0001651 In Scheme HI, a b cyclic aminoester of formula' la, wherein ¾ is' tert-hvtyl, is reacted with a protected amino acid, of formula 26 (wherein. Zj is an amine protecting grou and ca be removed under acidic, basic, or hydrogenating conditions dif ferent from those used for removing an 2 protecting group) in the presence of a coupling reagent, to gi e an amide-ester of formula 10. The protecting group ¾ is removed from the¾mide ester of formula 10 to give the amme-ester compound, o f formul 2S,
[000.166J In another embodiment eoinpoun.ds: of formula 28 are intermediates in the synthesis of protease inhibitors according to Scheme IV .
Figure imgf000033_0001
'1008168] In Scheme IV, the bicyclic aminoester of formula la, which cam be. prepared as described herein, wherein ¾ is rm-butyl, is reacted with a protected amino acid of formula 26 (wherei.il Zi is an amine protecting group and can be removed under acidic, basic, or hydrogenaimg conditions different from those used for removing the ¾ protecting group) in the presence of a coupling reagent, to give an amide-ester of formula 10. The protecting group Z> is removed from the amide-ester of formula 10 to give the amine-ester compound of formula 28. Reaction of the ammo-containing. compound of formula 28 with, the protected amino acid 29 in the presence of a coupling reagent gives a tripeptide of formula 30.
Removing the protecting group Z in the tripeptide. of formula 30 provides a tree amino- tripeptide of formula 31. Reaction of the aniino-tripeptide of formula 31 with the pyra ine-'2- carbosyHc acid of formula. 32 in the presence f a coupling reagent yields the amide- tripeptide ester of formula 33. Hydrolysis of the ester of the amide- iri peptide ester of formula 33 provides the amido-tripeptkie acid of formula 34. Reacting the amido-tripeptide acid of formula 34 with the amino-hydroxy amide of formula 18 to the presence of a coupling reagent gives the hydroxy-peptide of formula 35. In the final step, oxi dation of the hydroxy grou of the compound of formula 35 pro vides the compound of formula 4.
f(MIM6*>j In another embodiment, the process of Scheme HI can be scaled for large-scale production, e.g. in a manufacturing plant. Large scale production can. for example, be sealed to greater than .1000 kilos.
|888170) Although in parts of Schemes I to IV. only a single isomer is illustrated for some of the compounds:, the present invention is intended to include all stereoisomers of the compound.
)8881 :i]The following non-limiting examples are set. forth so that the present invention is more .folly understood. These examples are for the purpose of illustration only and are not t be construed, as limiting the scope of the invention in any way.
Examples
Example I : ~fe?-hu oxyea^ (6),
Figure imgf000034_0001
Method !
($00172 } Unde'r .nitrogen, 3-a^bieycio[3.3v(}}Ronane hydroe 0ride. (1 OO g, 0.677 mol), potassium carbonate ( 187 g, 1.35 mol), MTBE (220 mL). and w er (160 mL) were charged, with stirring, to a .2 L 3-necked round- bmt m flask fitted with a mechanical stirrer, a 500 ml, addition funnel, and a thermometer. The mixture was cooled to 14 to 16. °C. BocjO (ώ-ieri· butyl dicarbonate) (145 g. 0.644 mo!) and 'fBE (1 0 mL) was charged to a 500· mL
Erlenmeyer flask. The mixture a : stirred until dissolution was■complete. The solution was poured into the addition funnel and added to the reaction mixture, keeping the reaction temperature below 25 ^C, Water (290 mL) was added to dissolve solids, and the mixture was stirred for 10 to 15 minutes. After removin the aqueous phase, the organic phase was washed with 5% aqueous NaHSQ (twice, 1.45 mL each), then, water (1 5 mi...). The organic phase was concentrated,, and MTBE was added ( 1 .3 L) to give a solution of the title compound in MTBE. See, e.g., SLGrio Η . Chim. Acia. 2-: 67 ( 1959).
Method 2
|000Ϊ73] A solution of potassium carbonate ( 187 g, 1.35 mol) in. water ( 160 mL) was added t , .mixture, of 3-azabtcyek>[3..3,0:]oetane hydrochloride ( 100 g. 0.677 mol.) and MTBE (220 mL), and the resulting mixture was cooled to 14 to 16 ,3C. A solution of Boc?0 (145 g, 0.644 mol) in MTBE (190 mi) was added while maintaining a temperature below 35 *¾< After the addition, the mixture was stirred for 1 hour, then filtered. The solids were washed, with MTBE (50 mL). The phases were then separated, and the organic phase was washed with 5%. aqueous NaHSCX; (twice, 145 mL each) and water (1.45 mL). It was then concentrated to 300 mL unde vacuum. MTBE (300 mL) was added, a d the mixture was concentrated to reduce the water concentration to less tha 550 ppm. The concentrate was diluted with -MTBE (400 mL) to provide a solution of the title compound in MTBE.
Example 2.: (i$,3aR, aS)~ e^baiyl 2n((S}-2-{b *i^
dimeih lbttiandyl)0c^
Figure imgf000035_0001
26 i 27
Method 1
10 0! 74] A 3 L 3 -neck round bottom flask equipped with an overhead stirrer, condenser, thermocouple, and nitrogen outlet was purged: ith nitrogen for several minutes. In separate flask, sulfuric acid (46.2 mL, 0.86? mol) was diluted with 442 mL of water. The solution was allowed t cool slightly. Cbz-L-/m Leucine dieyelohexyiannne salt (330.0 g, 0.739 mol) was charged to the reaction flask. ΜΎ Ε (1620 mL) was add d to the reactor, and the mixture was stirred to suspend the salt, The sulfuric- acid solution prepared above was added to the reactor over about 10 minutes, keeping the temperature at 20 5 °C, The mixture was stirred at room temperature for approximately 1 hour, then diluted slowly with water (455 mL). Agitation was stopped, and the layers were allowed to settle. The aqueous phase was withdrawn to provide 1100 mL colorless solution of pH 1. To the organic phase remaining in. the flask was charged additional water (200 mL). The mixture was stirred at room temperature for approximately 1 hour. Agitation was stopped., and the layers were allowed to settle. The aqueous phase was withdrawn to provide 500mL colorless solution of pH 2. The organic phase was heated to about 35 °C, diluted with DMF (300 mL), and concentrated at reduced pressure to the po nt at which distillation slowed significantly, leaving about 500 mL of concentrate. The concentrate.was iransfcrred without rinsing to a 1 L Schot batik. The concentrate, a clear colorless solution, weighed 1 1.6 g, Eksed on solution, assay analysis and the solution weight, the solution contained 187,2 g (0.706' mol) of
Figure imgf000036_0001
[000175] To a 5 L 4-n.eck round, bottom, flask equipped with an overhead stirrer,
thermocouple, addition funnel and nitrogen inlet were charged H0BT«i¾( (103.73 g. 0.678 mol 1 .20 molar eq.), EDC'HCI (129.48 g, 0.675 mol, 1 .20 molar eq.% and DMF (480 mL). The slurry was cooled to 0 to 5 °C. A 36.6 weight percent solution of the acid of Cbz-L-fer/- Leueine in DMF (4 1.3 , 0.745 mol., 1.32 molar eq.) was added over 47 minutes to the reaction mixture, while keeping the temperature at 0 to 5 °C. The reaction mixture was stirred for 1 hour and .27 minutes. A. solution of 3-a¾ah5eycl.o(3,3.0)oetane-2-carboxylic acid- i m i ester in isopropyi acetate (28.8 weight percent, 4 Γ4.3 g, 0,564 mol) was added over 53 minutes, while keeping the reaction, temperature at to 5.1 The reaction mixture was warmed to 20±5 °C over about 1 hour. 4-Methylmorpholine (34.29 g. 0.339 mol, 0.60 mola eq.) was. added over 5 minutes. The reaction mixture was agitated for 16 hours, and then isopropyi acetate (980 mL) was added to the .reaction, solution. A solution of histamineft2HCl (41.58 g, 0.226 mol, 0.40 molar eq.) in water (53.02 g) was added to the reaction mixture within 4 minutes, followed by 4-met yimorphoime (45.69 g, 0,45- mol, 0J0 molar eq.}. The; reaction mixture was sampled after 3,5 hours. Water (758: mL) was added, and the ndxture was stirred for about 20 minutes, then allowed to settle for 1 1 minutes. The phases were separated. The aqueous phase was; extracted with isopropyi acetate (716 m.L), and the organic phases were combined, 1 aqueous hydrochloric acid was prepared by adding 37 weight percent hydroehlorie acid;C12¾.3 ml) to water ( 1435 mi). The organic phase was washed for about 20 minifies with the 1 N hydrochloric acid. A 10 weight percent aqueous potassium, carbonate solution- was prepared by dissolvin potassium: carbonate (171 g, 1 .23 rool, 2.1 molar eq.) in water ( 154D nil,). The organic phase was washed with, the 10 weight percent aqueous-potassium carbonate solution for about 20 minutes. The .final clear, pale yellow organic solution (1862.1 gL was sampled and submitted for solution assay. Based on. the solution, assay and the weight of the solution, the solution, contained 2.38.3 g (0.520 tnoi) of product of the title compound,
[000176} li! (D SC i* SOa MHz): δ 7.37 ppm (5 H, s), 7.25-7.33 ppm (1 H, m), 5.03 ppm (2 11 s). 4Λ 7 ppm (1 11 d), 3.98 ppm ( 1 It d 3.67-3.75 ppm (2 H, m), 2.62-2.74 ppm (1 H. ra), 2.48-2.56 ppm (1 11 m), 1.72-1.89 ppm (2 H, m-},. f .60-1.69 ppm (1 1-1, m), 1 .45- 1 ,58 ppm (2 H, ml 1.38 ppm (9 11 s , 136-1.42 ppm (1 11 m>, 0.97 ppm (9 11 s),
Method 2
[000177] A solution of potassium carbonate .(73 g) in water (220 mL) was added to a suspension of (1 S, 2S,5R) 3-azabieyeio[3.3.0]oetane~2~catboxyik^
(80.0 g.) in isopropyl. acetate. (400 mL) .while-maintaining a temperature of about 20 "C. The mixture was stirred lor 0.5 hours, the phases. were separated, and the organic phase was washed with 25 weight percent aqueous potassium carbonate (80 mL) to give a solution of the free base. In a separate flask, aqueous sulfuric acid (400 ml.,, 0.863 M) was added t suspension of Cbz-fM-leoeme dieyelohexvl-aniine salt (1 1 8.4g) in. ^r '-butyime-tliyl ether (640 ml.) while maintaining- a temperature of about 20 °C. The mixt ure was stirred for 0.5: hours, the phases were separated, and the organic phase was washed with water (200 mL). The phase, were separated, and ~methyim rpholine (80 mL). was added to the organic phase,, whieh was concentrated at reduced pressure at 40 ¾ to 80 ml., to give the free acid as a solution in N-inethymorpholine. This solution, was added to a mixture of EDO HQ (50.8 g) and HOBt hydrate (40.6 g) in N-methylmorpholirie (280 mL) at 0 to 10 °C. The mixture was stirred for 1 hour at about 5 "C. The solution of 3-azabicyclo 3.3.0]oetane~2-earboxylic. teri- butylesttr from, above was added at 0 to 20 ! C, followed by N-methy morpholine (32 mL). The mixture was stirred fo 6 hours, then diluted with isopropyl acetate (600 mL) followed by I N hydrochloric acid (400 mL), After stirring 0,5 hours, the phases were separated and the organic. hase was washed with 25 weight percent aqueous potassium carbonate (400 mL) and water .(80 mL). The mixture was stirred for about ! hour, and the phases were separated to give a solution of the title compound in isopropyl acetate. Method 3
000Π81 8/2$,5Ε) 3-^^
was suspended in Lsopropyj. acetate (6 vol ). arid a . -solution of potassium carbonate (3.0 eq.) in water (3.5 vol.) was added at 20 to 25°C. The mixture was stirred for 3 hours, then the phases wer separated. The organic phase was washed with water (2 vol).
£080179 j Cbz~to- -.leucme dlcyeloh xyiainin salt (1 .05 eq.) was suspended in isopropy! acetate (6 vol), and sulfuric acid (1 .3 eq.) in water (5 vol.) was added at 2 to 25°C. The mixture was stirred for 30 minutes* the phases were separated, and. the organic phase wa washed with water (2 times, 2.5 vol.).
J 000181 ] The two solutions from above were combined and then cooled to 0 to 5"C. MQBt hydrate (1.1 eq.) and BDC ( IJ eq,) were suspended in the mixture, and the mixture was stirred for 6 hours. The mixture was washed with water (5 vol.), nd the resulting organic phase was treated with L-iysifte ( 1 eq.) and N-methylnrorp.holine (2 eq.) a 20 to 25BC to destroy excess activated ester. The mixture was then washed with 5 percent potassium carbonate (5 vol.), 1 hydrochloric acid (5 vol.), 5 percent potassium, carbonate (5 vol), and water (twice, 5 vol.) to give a solution of the title compound in isopropyl acetate.
Example 3: (lS aH,6aS)-ii? ?~b«tv! 2-((S)-2-ainino~3,3-d5raethylbutanoyl)- oetah dr oeyciopeata [c] py rrole-i -carhoxy!ate (28 .
Figure imgf000038_0001
(000.1 SI) A 1 L Buchi hydrogenator was purged with nitrogen, three times, A 307.8 g portion of a 12.8 weight percent solution, of (1.S,3-a.R,6aS)- ^-butyl 2-((:S -2- {b£nzyloxyearbony!a mo)-3^
earboxyJate (as prepared by the method of Example 6, Method, t) in isopropy! acetate (3.9.39 g, 0.086 mol) was charged to the reactor, Isopropy! acetate (100 mL) was added to the reactor, A slurry of 50% water and wet 20% Pd( 01¾/earbon (3.97 g) in isopropyl acetate (168 m.L) was prepared and charged to the reactor, and agitation was started. 'The reactor was pressurized to 30 psig with nitrogen gas and vented, down to atmospheric pressure. This was repeated twice. 'Then, the reactor was pressurized to 30 psi with hydrogen and vented down to atmospheric pressure. This, was repeated twice. The reactor was pressurized to 30 psig with hydrogen and stirred, at mbient temperature for 1 hour. The mixture was filtered using a Buehner funnel with a Whatman #! filter paper to remove the catalyst. The filter cake was. washed with isopropyi acetate (SO mL), The ocedur was repeated twic more using 617 g and 290.6 g of the 12.8 weight percent solution of the starting compound. The material from the thre hydrogenations were combined and distiiied at reduced pressure (28 torr). The resultant solution (468.68 g) was assayed for the titl compound,
[000182) lR NMR (DMSC-d^ 500 MHz): δ 3.96 ppm ( I H, d), 3.67 ppm (1 H, dd)s 3.53 ppm (1 IT dd); 3.19 ppm ( I H, s), 2.66-2.75 ppm fl II m)} 2.49-2.53 ppm (1 IT ), 1 ,75- 1.92 ppm (2 IT m), 1 ,66-1 ,74 ppm. ( I B r m , 1.48. .60 ppm (4 H, m), 1 ,38 ppm (9 H, s)s 1.36 .42 ppm (1 l ro)y 0.91 ppm (9 IT s)
Method 2
[000183) The solution of the Cbz deri ative 27 ten Example 6, Method , was added to 20% Pd(Of-I)2/water (50%, 12.2 g) in a hyclrogenation apparatus. The apparatus was pressurized to 30 psi with hydrogen, then stirred for 2 hours at about 20 -eC. The mix ure was filtered to remove the catalyst and the filter cake washed with isopropyl acetate (160 mL). The combined filtrates were evaporated with about 4 volumes of heptane at 40 CC 2. to 3 times to remove the isopropyl acetate. The resultant slurry was cooled to 0 "C ami filtered, and the- product was; dried at reduced pressure to give the title compound.
Method 3
[00M841 A solution of (1 S,3aR;6aS)-/e?-/-butyl 2-((S)-2^am.ino-3 -dim:ethyibutanoyi octahydrocYciopenta[c]pyrrole-i -carboxyiate in isopropyl acetate from Example 6, Method 3. was added t 20% .I (Q!¾ (2 weight percent loading, 50 percent wet) and the mixture was hydrogenated at 2 bar and 20 to 25 °C for 2 hours. The catalyst was removed by filtration, and washed with isopropyl acetate (2 vol.). The filtrate was concentrated to 10 vol. at reduced pressure at 40 ' *C to give a solution of the title compound in isopropyl acetate.
(000185] White we have presented a number of embodiments of this invention, it is apparent, that our ba c constitution can be altered to provide other embodiments which utilize the compounds and. method of this invention. Therefbre. it will be appreciated that the scope of this invention is to be defined by- the appended, claims rather than by the specific
embodiments which have been represented by way of example.

Claims

What is claimed is:
i . A process for preparing c'nantioseleciively a compound of formula la or lb:
Figure imgf000040_0001
la
over a compound of formulas k - Ih:
Figure imgf000040_0002
Id le
Figure imgf000040_0003
f f l lh comprising the step of arboxylattng a compound of formulas Ila or lib:
Figure imgf000041_0001
in the presence of a compound of formula III:
Figure imgf000041_0002
IH
wherein:
.ring A is a C3.12 eyeloa!i haiie ring
ring B is a C3.12 heterocyctoaHphatic ring containing additional 0 to 2 heteroaronts, each mdependenily seiected from 0, f and .S, wherein ring B is optionally: substituted with 0 to 4 groups, each independently selected -from afk l halo, aikoxy. aryl, and hydroxy;
Rs is H or a protecting group;
Ri;i is a protecting group;
R; is ! h a protecting group, or C 5 .1 aliphatic; and
R'3 and R are each independently a protecting group, C\.n aliphatic, or a cyclic group selected from the group consisting of cycloaliphatic,
heieroeydoaliphatic, aryl, .and heteraaryl.
The process of claim 1 , wherein ring A is a eycloaliphaiic ring. The process of claim 2. wherein ring A is eyelopeniyl. The process o f claim 3 , where n ring A
Figure imgf000042_0001
The process of claim.2, wherein ring A is cyclopropy l.
the process of claim 5, wherein ring A is J -dime iyleyciopropy!
l re process of claim 6, wherein ring A. Is
Figure imgf000042_0002
The process of claim' Γ, wherein ring B is aryl.
The process of claim 8, .wherein ring B is phenyl
The process of claim: 9. wherein rin ;
Figure imgf000042_0003
The process of claim 1 , wherein ring B is 5-mem'bered heterocyclic ring.
The process of claim 1 1 , wherein ring B is
Figure imgf000042_0004
.1 The process of claim I ', wherein ring B is substituted with an aryl ring optionally substituted with 0 to 4 groups, each independently selected from t e group oansisting of aikyi, halo, aikoxy, -and hydroxy!,
14. The: process of claim
Figure imgf000043_0001
15. The process of claim 1 , wherein i is 1 1.
16. The process of claim 1 , wherein R} is a protecting group,
17. The process of claim 16, wherein } is ferr-butyl carbamate (Boc), 1 The process of claim 1 , wherein K;a i a protecting gronp,
1.9. The process of claim 1. H. wherein ]» is /crz-bntyi carbamate' (Boc).
20. T!ie process of claim 1, wherein ¾ is I I.
21 . The process of claim 1 , wherein 'R3 is€s .52 aliphatic.
22. The process, of claim 1 , wherein R3 is C a!kyl
23. 'The process of claim 22. wherein R2 is selected from the group consisting of methyl, ethyl w- ropyL Mo-propyi. Lw-h xyL ieriA iyh ;?~butyL «~pentv and ^o- t l
24. 'fhe process of claim 23, wherein R? is ft?^ butyl.
25. The rocess-ofc m 21 , wherein ¾ is. a cyeioaliphaiic ring,
26. The process of claim 1 , wherein the step of-earboxylating a compound of formula I!a or O : is . in presence f the compound of formula Ola:
Figure imgf000044_0001
27. The process of -claim. 1, wherein, the step of earboxylating a compound of formula 11a or lib is in presence of th
Figure imgf000044_0002
Illb
28. The process, of claim 1 , wherein the step of earboxylating a compound of formula ITa or li b is. in presence of
Figure imgf000044_0003
Ilk 9, The process of claim. 1 , wherein the step of carboxylating a compound of formula 11a or lib s hi. presence of, the compound of formula Hid:
Figure imgf000045_0001
ilM
30, The process of claim L wherein the step of carboxylating a compound of formula Ha or lib is in presence
Figure imgf000045_0002
31., The process of claim: L wherein ¾ is CY12 aliphatic.
32, The process of claim. 31.. wherein R? is C1 unbranched aikyl
33, The process of claim 1. wherein R,? is C1 branched aikyl
34. The process of claim I . wherein R.¾ is CM branched aikyl .substituted with a cyclic group.
35, The process of claim 34, wherein ¾ is CM branched aikyi, substituted with a phenyl group.
36. The process of claim I, wherein R,i is a cyclic group.
37. The process of claim 36, wherein R is a: tricyclic group.. The process of claim 1. wherein the earboxylaiion step comprises treating
compound of formula 1.1 with carbon dioxide and a lithium .base in an aprotie solvent.
The process of claim 38; wherein the aprotie solven is selected from toluene ethyl acetate, benzene, and. methyl ten-hafyl ether ΜΎΒΕ,
The process of Claim.39» wherein the aprotie solvent is TtSE,
The process of cl aim 38, wherein the lithium base is s c-but l lith ium .
The process of claim 1 , wherein the combined weight percent in the mixture comprising compounds of formiila la and Id (the evo-isomers) and compounds of formula ic and le (the ioAmxmxs) is ICQ weight percent.
The process of claim 42, wherein the exoi ndo ratio is at least 60 to 40,
The process of claim 1 , further comprising removing a portion of the compounds of formula lc and le from the mixture.
The process of claim. 44. wherein the compounds of formula Ic and le are removed by crystallizing the compound f formula ia.
The process of claim 44. wherein the compounds of formula l.c and le are removed by reerystaU .ing the compound of formula la.
The process of claim 1 , wherein the ratio of the weight percent of la to id at least 60 to 40.
A. process tor preparing a compound of formula 1:0:
Figure imgf000047_0001
10
comprising the ste s of:
a. forming a 2-an.ioii of a compound of formula
Figure imgf000047_0002
Ik
i the presence of a compound. of formula 1 f :
Figure imgf000047_0003
Hi
treating the anion of step a with carbon dioxide to produce enantioselectively a compound of formula !a and
reacting the compound of formula la with a compound of formula 26,
Figure imgf000047_0004
26
in the presence of a coupling reagent;
wherein:
ring A. is a C3.12 cycloaHphatic ring:
.i is H or a protecting group: R> is I I, a protecting group, or CM 2 aliphatic;
R3 and ¾ arc each independently a protecting,
Figure imgf000048_0001
aliphatic, or a cyclic group selected from the group consisting, of cvcloaliphatic,
heterocycioaiiphaiic, aryL and heieroaryl;
Z2 is H or a protecting group; and
2A is a protecting group.
The process of claim 48 wherein the compound of fortmi!a III i formula if la:
Figure imgf000048_0002
Ufa
The process of claim 4S wherein the compound of foranila ΠΪ is formula H'l'br
Figure imgf000048_0003
nib
The process of claim 48 wherein the compound of formula III is formula Die;
Figure imgf000048_0004
The process of clai II is formuia Hid;
Figure imgf000049_0001
Hid
The- rocess of claim a ill is formula Hie:
Figure imgf000049_0002
file
4. The process of claim 4S, wher of formuia 26 is .formula.26-a:
Figure imgf000049_0003
26-a
5. The process of claim 48* wherein d of formula 26 is formula 26-b:
¾rN
Figure imgf000049_0004
6. The process of claim 48„ la 10 is formula 1'0-a:
Figure imgf000050_0001
1 -a
"he process of claim 56, wherein Zj: is H. and is /ert-butyl
58. The process of claim 48. wherein the compound of formula 10 is formula 10~h;
Figure imgf000050_0002
10-b
59. The process: of claim 48. wherein ihe compound of formula 1 is formula 10-e:
Figure imgf000050_0003
60. The process of claim 59, wherein Zs is H, and ¾ is te/t-buty L
1. The process of claim 48, la 10 is formula 1.0-d:
Figure imgf000050_0004
10-d A process for preparing compounds of formula 4:
Figure imgf000051_0001
comprising the steps of:
a. .reacting a compound of formula H-a with a base and€¾ in the presence of a compound of formula ΪΠ to prepare a compound of formula 1 - 1 a:
b. reacting the a compound of formula la with a compound of formula 26 in. fits presence of a coupling reagent to form a compound, of formula 10:
c. removing ¾ from the compound of formula 10. o give a compound of formula
Figure imgf000051_0002
28
d. reacting the compound of formula 28 with a compound, of formula 2:9:
Z-!-S L OOH
2
In the presence of a ound of formula 30:
Figure imgf000051_0003
wherein Z is an amine proteeting-group;
removing the protecting group Z in the compound of formula 30 to give a compound of formula 1 :
Figure imgf000052_0001
react ng the -compound of formul 31 w th, a compound, of formula 3.
Figure imgf000052_0002
32
in the presence ula
Figure imgf000052_0003
hydrolyzbig the ester of the compound of formula 33. to give a compound oi formula 34;
Figure imgf000052_0004
reacting the compound of formula 34 wit a compound of formula 18:
Figure imgf000052_0005
m the presence of a coupling reagent to give a compound, of formula 35;
Figure imgf000052_0006
i oxidizing the compound of formula 35 to give the compound of formula 4.
I'he process of claim 62, wherein, the process is seated lor large scale production.
A compound of formula ia-1 prepared by the process of claim
Figure imgf000053_0001
i a- i
A compound of formula la -2, prepared by the process of claim 1 :
Figure imgf000053_0002
A compound of formula a-3 process-: of claim-
Figure imgf000053_0003
a-.»
A eompoun . of the f rmul !a~ by the process of claim 1 :
Figure imgf000053_0004
H A compound of formula -a made by ih processes of claim 48:
Figure imgf000054_0001
10-, A compQMsnd of formula 10-b made by the processes of claim 48:
Figure imgf000054_0002
, A compound of form -c made by the processes of claim 48:
Figure imgf000054_0003
10-c
. A, compound o fformuJa 10-d made by the processes of claim 48;
Figure imgf000054_0004
1 0-d
PCT/US2012/037515 2011-05-13 2012-05-11 Process for the preparation of protease inhibitors WO2012158515A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201280034614.0A CN103748059A (en) 2011-05-13 2012-05-11 Process for the preparation of protease inhibitors
EP12723028.2A EP2707346A1 (en) 2011-05-13 2012-05-11 Process for the preparation of protease inhibitors
IL229427A IL229427A0 (en) 2011-05-13 2013-11-13 Process for the preparation of protease inhibitors
HK14110522A HK1197229A1 (en) 2011-05-13 2014-10-22 Process for the preparation of protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486150P 2011-05-13 2011-05-13
US61/486,150 2011-05-13

Publications (1)

Publication Number Publication Date
WO2012158515A1 true WO2012158515A1 (en) 2012-11-22

Family

ID=46147756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037515 WO2012158515A1 (en) 2011-05-13 2012-05-11 Process for the preparation of protease inhibitors

Country Status (5)

Country Link
EP (1) EP2707346A1 (en)
CN (1) CN103748059A (en)
HK (1) HK1197229A1 (en)
IL (1) IL229427A0 (en)
WO (1) WO2012158515A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007022459A2 (en) * 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2008082508A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Process for the preparation of 6,6-dimethyl-3-azabicyclo- [3.1.0]- hexane compounds utilizing bisulfite intermediate
WO2011153423A2 (en) * 2010-06-03 2011-12-08 Vertex Pharmaceuticals Incorporated Processes and intermediates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2002000136A (en) * 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007022459A2 (en) * 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2008082508A2 (en) * 2006-12-20 2008-07-10 Schering Corporation Process for the preparation of 6,6-dimethyl-3-azabicyclo- [3.1.0]- hexane compounds utilizing bisulfite intermediate
WO2011153423A2 (en) * 2010-06-03 2011-12-08 Vertex Pharmaceuticals Incorporated Processes and intermediates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HENDRATA S ET AL: "Syntheses of dipeptides containing (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxylic acid (4), (1R,5S)-spiro[3-azabicyclo[3.1.0]hexane-6,1'-cyclopropane]- 2(S)-carboxylic acid (5) and (1S,5R)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxylic acid (6)", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 47, no. 36, 4 September 2006 (2006-09-04), pages 6469 - 6472, XP025004794, ISSN: 0040-4039, [retrieved on 20060904], DOI: 10.1016/J.TETLET.2006.06.052 *
VALENTIN KÖHLER ET AL.: "Enantioselective Biocatalytic Oxidative Desymmetrization of Substituted Pyrrolidines", ANGEW, CHEM. INT. ED., vol. 49, 2010, pages 2182 - 2184, XP002679204 *

Also Published As

Publication number Publication date
IL229427A0 (en) 2014-01-30
HK1197229A1 (en) 2015-01-09
CN103748059A (en) 2014-04-23
EP2707346A1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
JP4672647B2 (en) Process for producing N-substituted 2-cyanopyrrolidine
EP3068387A1 (en) Compounds and methods for the treatment of malaria
JPH09508416A (en) HIV protease inhibitors and intermediates
JP7025411B2 (en) Method for producing indole carboxamide compound
AU2013326850A1 (en) Novel compounds, their preparation and their uses
ZA200604240B (en) Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical purity
JP2020531500A (en) (S) -TERT-Butyl 4,5-diamino-5-oxopentanoate preparation process
JP2023103364A (en) Compound, pharmaceutically acceptable salt or stereoisomer thereof, and use thereof
WO2012158515A1 (en) Process for the preparation of protease inhibitors
CN101687783B (en) 4-(trichloromethylthio)aniline, method for producing the same, and method for producing 4-(trifluoromethylthio)aniline
EP3658569B1 (en) Process and intermediates for synthesis of peptide compounds
US11420959B2 (en) DACOS type NNRTIS amino acid ester derivative, preparation method thereof, pharmaceutical composition, and application thereof
ZA200507396B (en) Process for the preparation of n-substituted 2-cyanopyr-rolidines
SK16332002A3 (en) A process for preparing biphenyl compounds
CZ2003419A3 (en) Process for preparing alpha-chloroketones
JP2009504627A (en) Preparation of diazapentane via epoxy reaction of dihydropyrrole
KR102518994B1 (en) Processes for the preparation of azd5363 and novel intermediate used therein
KR20190039087A (en) Purified intermediates for the preparation of purified &amp;lt; RTI ID = 0.0 &amp;gt; Senicry &amp;lt; / RTI &amp;
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
JP2020505336A (en) Method for producing chiral pyrrolidin-2-yl-methanol derivative
WO2022117012A1 (en) Spirocyclic jak inhibitor, pharmaceutical composition containing same, and application thereof
KR20050008664A (en) Process for the preparation of morpholine derivatives and intermediates therefore
SK19062001A3 (en) Process for preparing (-)-(1S,4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters
JPS6270344A (en) Production of nitrophenoxyamine
US20200039975A1 (en) Processes for the preparation of a bace inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12723028

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012723028

Country of ref document: EP